Posts by acn:

Advertising, Media and Education Sectors Lead Singapore’s Job Market Amid Modest Recovery

Key Highlights:Hiring activity in Singapore saw recovery with a 3% month-on-month growth while witnessing an annual dip of 5% in February’25Advertising, Public Relations & Media sector and the Education sector lead with 7% month-on-month growth in February '25Hiring for Software, Hardware, and Telecom roles record the highest growth at 2% month-on-month Legal sector saw the strongest annual growth at 19% year-on-yearSINGAPORE, Mar 24, 2025 - (ACN Newswire via SeaPRwire.com) - foundit (formerly Monster APAC & ME), one of the leading jobs and talent platform, today published the foundit Insights Tracker (fit) Singapore for February 2025. The Singapore fit report highlights growth in the Advertising and Education sectors alongside rising demand for technology professionals.The tracker reveals an overall year-on-year (YoY) decline of 5% in hiring activity across sectors, as the index dropped from 108 in February 2024 to 103 in February 2025. However, a month-on-month (MoM) analysis indicates a 3% uptick,Commenting on Singapore's job trends for February 2025, V Suresh, CEO, foundit, said,“The February 2025 foundit Insights Tracker signals a promising recovery in Singapore’s job market. While year-on-year figures reflect ongoing economic recalibration, the month-on-month growth indicates a resurgence in hiring activity. The robust expansion of sectors such as Advertising, Media, and Education, coupled with the growing demand for technology professionals, underscores shifting industry priorities and workforce evolution. As digital transformation accelerates, Singapore’s job landscape is stabilizing, with a strong emphasis on upskilling, adaptability, and future-ready talent."Advertising, and Education sectors lead industry growth, while Engineering and Retail sectors show strong improvementsThe Advertising, Market Research, Public Relations, Media, and Entertainment sector has emerged as a frontrunner in e-recruitment activity among all monitored industries, showing a 7% MoM growth in February 2025. This growth is driven by increased digital marketing efforts and brand-building strategies.Equally impressive, the Education sector also recorded 7% MoM growth in February 2025, reflecting a continued emphasis on workforce upskilling and professional development.Following these leaders, the Engineering, Construction, and Real Estate sector showed positive trends with 6% MoM growth, while the Retail, Trade, and Logistics sector experienced 5% MoM growth, both driven by sustainability initiatives and evolving business needs.Several sectors show modest growth while others remain stableThe Production/Manufacturing, Automotive, and Ancillary sector demonstrated positive hiring momentum with 5% MoM growth in February 2025.Several sectors showed more modest growth, with Hospitality & Travel, IT, Telecom/ISP, and BPO/ITES, BFSI, and Healthcare all registering 2% MoM increases, signalling steady job creation across these industries.Conversely, multiple sectors including Oil and Gas, Import/Export, Shipping/Marine, Government/PSU/Defence, and Consumer Goods/FMCG exhibited stagnant hiring activity with 0% MoM change.Technology roles lead demand among functionsIn terms of functions, Software, Hardware, and Telecom witnessed the highest demand in February 2025, with a 2% MoM increase. This trend underscores the growing need for tech talent amid ongoing digital transformation initiatives.Marketing & Communications, HR & Admin, Engineering/Production, Sales & Business Development, Medical Roles, and Legal roles all showed modest but positive growth at 1% MoM, indicating broad but measured hiring activity across professional functions.The roles in Legal experienced a robust   19% YoY increase in hiring activity, highlighting the rising need for legal professionals amid evolving regulatory landscapes, corporate expansions, and compliance requirements.However, Hospitality Roles, Customer Service, Finance & Accounts, and Purchase/Logistics/Supply Chain roles saw no changes (0% MoM), reflecting a period of stability in workforce demand across these functions.The foundit Insights Tracker is a comprehensive monthly analysis of online job posting activity conducted by foundit. Based on a real-time review of millions of employer job opportunities culled from a large, representative selection of online career outlets, the foundit Insights Tracker (FIT) presents a snapshot of employer online recruitment activity nationwide.About foundit - APAC & Middle Eastfoundit, formerly Monster (APAC & ME), is Asia’s leading jobs and talent platform offering comprehensive employment solutions to recruiters and job seekers across APAC & ME. In addition to its innovative AI-powered job search, foundit offers e-learning, assessments, and services related to resume creation and interview preparation. foundit has connected over 120 million job seekers across 18 countries with the right job roles and upskilling opportunities. Over the last two decades, the company has been a leader in the world of recruitment solutions and has launched cutting-edge tools to give recruiters access to passive candidates in addition to active ones. With its advanced technology, foundit is efficiently bridging the talent gap across industry verticals, experience levels, and geographies.Today, foundit is committed to enabling and connecting the right talent with the right opportunities by harnessing the power of deep tech to sharpen hyper-personalised job searches and offer precision hiring. Additionally, foundit has been recognised as a Great Place to Work, reflecting its dedication to fostering a supportive and dynamic work culture.To learn more about, foundit in APAC & Gulf, visit: www.foundit.sg |www.foundit.com.ph | www.foundit.my | www.foundit.in | www.founditgulf.com | http://www.foundit.hk | www.foundit.id For media inquiries or further information, please contactNamrata Sharma – Namrata.sharma@adfactorspr.comContact number - +65 81383034 Copyright 2025 ACN Newswire via SeaPRwire.com.

中国电力(02380):新战略落地成效显著,经营性利润创历史新高

香港, 2025年3月24日 - (亚太商讯 via SeaPRwire.com) - "十四五"开篇以来,能源央企深入落实习近平总书记关于能源安全和绿色发展的一系列重要论述,统筹"保障能源安全"和"绿色低碳转型"两大任务,积极贯彻国家"双碳"战略,全力推动高质量发展。中国电力(02380)作为国家电投旗下清洁能源旗舰上市平台,是电力企业清洁转型和高质量发展方面最具有代表性的上市公司之一。智通财经APP了解到,中国电力3月20日发布2024年业绩公告,并在3月21日召开业绩发布会。该公司全年实现收入542.13亿元,同比增长22.48%,其中清洁能源收入322亿元,占总收入60%,同比提升了9个百分点。实现权益持有者应占利润38.62亿元,经营性净利润创上市以来历史新高。合并装机容量达到4939.1万千瓦,其中清洁能源占比80.12%。该公司计划宣派2024年度股息人民币0.162元/股,派息率60%;加上2024中期特别股息0.05元/股,全年派息总额0.212元/股,派息率达到78%,对应股息率超过7.7%。四年"翻一番",能源转型和业绩增长全面提速2021年,中国电力发布全新战略,步入清洁发展和创新驱动的转型快车道,清洁能源装机占比快速提升、资产质量持续优化、科技创新形成新的支撑,形成了清洁发展与科技创新"双轮驱动"、水火风光协同互济的发展格局。存量提质方面,成功对超600万千瓦亏损煤电开展煤电联营,快速堵住经营业绩"出血点",煤电板块度电盈利能力已从行业中下游跃升至领先地位。从转型的成效来看,2021年以来,该公司实现4年"翻一番":合并装机容量增加85%,资产总额增加118%,营业收入增长91%,归母净利润增长126%。聚焦科技创新与核心竞争力,扎实推进战新产业发展2021年以来,中国电力科技创新全面提速,在新型储能、储能安全、新型电力系统建设关键技术等领域掌握了一批技术。在新型储能领域,新源智储已获评北京市"独角兽",牵头建设应急管理部电化学储能安全重点实验室,推出了"智储-银河"系列超分子全浸没式工商业储能一体机,从源头上切断了发生火灾的可能性;在绿电交通领域,启源芯动力市场占有率保持行业领先,C轮融资投后估值达100亿元;在清洁供暖和地热领域,新源泰利建成房山区首个100%可再生能源供热制冷项目,获批共建地热院士专家工作站。分红金额逐年上升,以实际行动回馈股东2021-2024年,该公司每股派息从0.05元上升至0.162元,2021年利润受到火电的影响而亏损,但该公司依旧坚持派息,2022年恢复盈利后,三年的平均派息比例超过60%。拉长周期看,根据东方Choice数据,2004年以来该公司累计派息21次,平均派息比例达56.91%,在业内处于领先水平。而在分红的持续增长下,目前其股息率已具较大吸引力。高度重视资本市场,市值表现取得显著突破2021年以来,中国电力密集开展资产结构调整、收购母公司资产、股权激励、母公司增持、ESG管理、投资者关系等工作,在资本市场关注度逐渐提升。2021-2022年,中国电力股价上涨超过3倍,市值最高超过600亿港币,之后2年受大环境以及电力政策影响有所回撤。该公司管理层称,将全面加强市值管理,落实国资委关于加强中央企业控股上市公司市值管理工作的各项意见,研究各项市值管理工具利用,加大重视股东回报。值得注意的是,该公司持续获得各方看好:大股东国家电投近年持续开展增持;中信金融资产于2024年举牌并获得1名董事席位;而港股通资金也在持续流入,其中沪港通于最近60日净买入1.62亿股,截止3月21日持股比例13.78%,较2021年增长约10个百分点。此外,该公司也获得多家境内外投行看好,给予目标价均显著高于现价。综合来看,"十四五"开篇至今,中国电力加速内功修炼,向市场交出了一份靓丽的成绩单。在算力需求呈指数级增长导致全球开启电力竞赛的背景下,在能源政策支持电力企业高质量发展的趋势下,电力公司在资本市场有望获得估值回归。而中国电力凭借自身战略、资产结构等差异化优势,有望迎来更好的投资机会。 Copyright 2025 亚太商讯 via SeaPRwire.com.

GA-ASI Achieves EMAR/FR 145 Maintenance Organization Approval for MQ-9A and MQ-9B Platforms

SAN DIEGO, CA, Mar 21, 2025 - (ACN Newswire via SeaPRwire.com) - General Atomics Aeronautical Systems, Inc. (GA-ASI), a world leader in unmanned aircraft systems (UAS), has received the prestigious EMAR/FR 145 Maintenance Organization Approval for component maintenance from the French Military Continuing Airworthiness Authority, DSAE. This approval underscores GA-ASI's commitment to the highest standards of safety, compliance, and operational excellence in military aviation.The EMAR framework is a set of regulations developed from commercial aerospace standards (FAA/EASA) that are designed to ensure airworthiness for European military aircraft. It establishes a common airworthiness framework recognized by military airworthiness authorities worldwide. EMAR/FR 145 certification authorizes maintenance organizations to perform critical maintenance tasks while ensuring strict adherence to safety, reliability, and documentation requirements.GA-ASI's EMAR/FR 145 approval allows the company to issue EMAR Form 1s (Return to Service forms) for components serviced by the approved maintenance organization, confirming the safety and airworthiness of the equipment. This recognition applies to GA-ASI's maintenance activities at its Poway and Adelanto, California, facilities and covers CAT C (component maintenance) services."This approval is a significant achievement for GA-ASI, positioning the company to better serve international customers, especially military users of our MQ-9A and MQ-9B UAS platforms," said Sam Richardson, GA-ASI vice president of Sustainment. "The ability to leverage the EMAR/FR 145 certification streamlines the company's processes, reduces costs, and accelerates future airworthiness pursuits, as many future customers will recognize this certification rather than requiring a full, independent certification process."By obtaining EMAR/FR 145 approval, GA-ASI further demonstrates its ability to meet the stringent demands of the global defense market. The framework's widespread recognition ensures that GA-ASI can expand operations and offer high-quality, compliant maintenance services to international customers, ultimately driving company growth in global markets.This certification offers significant operational and financial benefits for both GA-ASI and its customers. For GA-ASI, the approval reduces future oversight costs by leveraging the DSAE Audit Team's oversight activities, ensuring a more efficient and cost-effective certification process for future non-French EMAR customers. For customers, the EMAR/FR 145 approval provides a framework recognized internationally, offering a streamlined maintenance certification process. The recognition agreements between EMAR and non-EMAR countries allow future customers to leverage GA-ASI's French approval, saving time and resources compared to a full certification effort.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 8 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle® 25M, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com.

ComfortDelGro Unveils Refreshed Corporate Brand — Drives Ahead With a Common Purpose and New Look

- ComfortDelGro, a leading multi-modal mobility transport operator, introduces a new purpose statement to reflect its commitment to driving positive impact for a better future. - Refreshed logo and corporate identity underscores the company’s journey as a global, progressive, and collaborative mobility leader. SINGAPORE, Mar 24, 2025 - (ACN Newswire via SeaPRwire.com) - ComfortDelGro Corporation Limited (SGX:C52) (“ComfortDelGro” or, “The Group”) today, unveiled its refreshed corporate brand, comprising a new purpose statement and modern visual identity that signifies a step forward in the company’s evolution into a global multi-modal transport leader. The Group has made significant strides in growing its international business, winning bus and rail tenders in Europe and Australia, as well as building leading positions for its point-to-point mobility businesses in key markets. With a presence in 13 countries, 24,500 employees, an operating fleet of over 54,000 vehicles and a rail network of 343 kilometres in operation and under mobilisation, ComfortDelGro is one of the largest land transport companies in the world. ComfortDelGro Managing Director/Group CEO Cheng Siak Kian said, “Our purpose statement – Mobility for a better future, drives us to reimagine mobility as a catalyst for positive impact as we accelerate our growth and navigate new horizons. It reflects our commitment to addressing the changing needs of our stakeholders as a global multi-modal transport leader. At the same time, it aligns the Group’s diverse operations and workforce under the common goal of building a purpose-driven and values-led organisation.” ComfortDelGro Chairman Mark Greaves added, “The transport landscape is evolving, and so is ComfortDelGro. We are committed to sustainable mobility, powered by innovation and driven by collaboration. This brand refresh underpins our journey forward as a global, progressive, and collaborative mobility company while building on the strong foundation of our businesses and our rich heritage. Our purpose ‘Mobility for a better future’ will guide us as we continue to create long-term value for our stakeholders, shape the future of transportation, and contribute to a more sustainable and connected world." Driven by our new purpose: Mobility for a better futureA modern identityComplementing our purpose statement is an updated ComfortDelGro logo that symbolises the company’s journey forward and its commitment to delivering innovative, world-class mobility solutions. Key elements include:A refined blue hue, representing reliability, trust, and customer confidence.A streamlined lowercase font, conveying approachability and collaboration.An enhanced arrow motif, reinforcing the company’s forward-thinking and dynamic approach.The updated brand and corporate identity will be gradually implemented in stages across the Group’s global operations.Media Assets:High-resolution images can be downloaded here: https://fromsmash.com/cdgbrandrefreshAbout ComfortDelGro CorporationComfortDelGro is a leading multi-modal transport operator offering a comprehensive suite of transportation solutions. Our extensive network spans public transport including buses and rail, point-to-point transport with taxis and private hire cars as well as business-to-business mobility solutions. Every day, millions rely on our services across 13 countries including; Singapore, Australia, the United Kingdom, New Zealand, China, Ireland, Sweden, France, Malaysia, Spain, Portugal, Greece, and the Netherlands. As a global operator, we play an important role in steering the transition towards a low-carbon economy. With about 60% of our owned fleet consisting of cleaner energy vehicles, we support governments and cities in enabling inclusive and sustainable transport systems. For our efforts, ComfortDelGro has been included in the Dow Jones Best-in-Class Indices since 2019, the only Singaporean transport company in the index. Media Contact Information:Group Corporate Communications  ComfortDelGro Corporation Limited groupcorpcomms@comfortdelgro.com  Copyright 2025 ACN Newswire via SeaPRwire.com.

Sino Biopharm (1177.HK) Announces 2024 Annual Results

Financial Highlights For the Year Ended 31 December RMB20242023Change RMB’BillionRMB’Billion(%)Revenue28.8726.20+10.2%Gross profit margin (%)81.5%81.0%+0.5pptSelling and administrative expenses to revenue ratio (%) *42.1%42.2%-0.1pptR&D expenses to revenue ratio (%)17.6%16.8%+0.8pptProfit for the year6.365.10+24.9%Profit attributable to owners of the parent **3.502.33+50.1%Adjusted non-HKFRS profit attributable tothe owners of the parent *** 3.46 2.59 +33.5%Basic earnings per share, based on adjusted non-HKFRS profit attributable to the owner of the parent (RMB cents) 18.90 13.97 +35.3%Sales of innovative products ****12.069.89+21.9%Share of revenue (%)41.8%37.8% Sales of new products*****10.098.05+25.4%Share of revenue (%)35.0%30.7% Dividend per share (HK cents)7.05.0+40.0%- Interim3.02.0+50.0%- Final4.03.0+33.3%*The total of selling and distribution costs and administrative expenses divided by revenue**The significant year-on-year increase in profit attributable to the owners of the parent was mainly driven by the notable growth in revenue and the gain on disposal of subsidiaries during the year***It refers to the basic earnings attributable to the owners of the parent after excluding impacts of discontinued operations, certain non-cash items and the share of profits and losses of associates and joint ventures.****Sales is the gross sales amount minus the sales discount. Innovative products include innovative drugs and biosimilars*****Products launched within five yearsDevelopment HighlightsOncology Innovative Drugs- Focus V (Anlotinib Hydrochloride Capsules) has been approved for seven indications. The marketing applications of three new indications have been submitted to the Center for Drug Evaluation of the China National Medical Products Administration (“CDE”), while another three pivotal clinical trials for new indications have shown positive results. The Group will submit new marketing applications to the CDE for these indications in the near future. In addition, anlotinib is in Phase III clinical studies for a number of new indications, including first-line non-squamous non-small cell lung cancer and first-line colorectal cancer. It is expected that marketing applications will be submitted gradually in the next few years.- Yilishu (Efbemalenograstim alfa Injection) has completed three global multi-center, randomized, and controlled pivotal Phase III clinical trials, and has been compared with the commonly used short-acting and long-acting G-CSF drugs in clinical practice, proving its efficacy and safety. In December 2023, Efbemalenograstim alfa was successfully included in the NRDL, and its sales volume accelerated in 2024, becoming an important contributor to the Group’s revenue growth.- Anfangning (Garsorasib Tablets) is a novel and highly effective KRAS G12C inhibitor that was approved for marketing by the NMPA in November 2024 for the treatment of advanced non-small cell lung cancer with KRAS G12C mutation that has received at least one systemic treatment. The Group will further explore the multi-indication potential of garsorasib, which is expected to become another blockbuster product in the oncology field.- Anbeisi (Bevacizumab Injection), Delituo (Rituximab Injection), Saituo (Trastuzumab for Injection), and Paletan (Pertuzumab Injection) were approved for marketing by the NMPA in February 2023, May 2023, July 2023, and December 2024, respectively. The rapid increase in the volume of these biosimilars in 2024 has accelerated the Group’s revenue growth.Liver Disease Innovative Drugs- Tianqing Ganmei (Magnesium Isoglycyrrhizinate Injection) is the fourth-generation of glycyrrhizic acid preparation that has been approved for three indications: chronic viral hepatitis, acute drug-induced liver injury, and improvement of liver dysfunction. Magnesium isoglycyrrhizinate is the world’s first 99.9% purified alpha-glycyrrhizic acid. It has the advantages of strong liver targeting, excellent anti-inflammatory effects, and good safety.- Lanifibranor (pan-PPAR agonist) is currently undergoing Phase III clinical trials worldwide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In July 2023, Lanifibranor was granted Breakthrough Therapy Designation by the CDE. Lanifibranor is China’s first MASH drug to enter Phase III clinical trials and is expected to fill the gap in China’s MASH market.Respiratory Innovative Drugs- Tianqing Suchang (Budesonide Suspension for Inhalation) is China’s first budesonide nebulized generic drug approved for marketing, breaking the long-term monopoly of branded drugs in the domestic market, and offering an effective, safe and economical high-end product for patients with chronic airway inflammation in China. The product has been included in the national Volume-based Procurement (“VBP”). The Group has taken a series of proactive management measures in a timely manner, including strengthening downstream channels, expanding market coverage and conducting secondary development in markets outside the scope of the VBP, enabling its sales to achieve steady growth in 2024.- Tianyun (Colistimethate Sodium for Injection) is a first-to-market generic drug launched in 2021. It is China’s first colistimethate sodium for injection approved for marketing, and was successfully included in the NRDL in 2023. At present, only two products with the same generic name have been approved in China. The Group continued to expand its market coverage through active academic promotion, and Tianyun’s sales grew rapidly in 2024.Surgery/Analgesia Innovative Drugs- Zepolas (Flurbiprofen Cataplasms) is the first domestically produced cataplasms approved for marketing in China, ranking first in the market share of topical analgesia for many years. Sales of flurbiprofen cataplasms have maintained a growth trend in recent years and achieved breakthrough growth in 2024. The second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing in 2025.Others- In 2024, the tenth batch of VBP products accounted for only 1% of the Group’s total revenue, and the related risks have basically been removed. In addition, Anboni (Unecritinib Fumarate Capsules) and Anluoqing (Envonalkib Citrate Capsules), two category 1 innovative drugs independently developed by the Group, were newly included in the NRDL and are expected to benefit more patients.HONG KONG, Mar 21, 2025 - (ACN Newswire via SeaPRwire.com) - Sino Biopharmaceutical Limited (“Sino Biopharm” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2024.During the year, the Group recorded revenue of approximately RMB28.87 billion, an increase of approximately 10.2% over last year. Profit attributable to the owners of the parent company was approximately RMB3.50 billion, a substantial increase of approximately 50.1% over last year. Earnings per share attributable to the owners of the parent company were approximately RMB19.13 cents, a significant increase of approximately 51.9% over last year, which was mainly driven by the notable growth in revenue and the gain on disposal of subsidiaries during the year. Excluding the profit attributable to the owners of the parent from the discontinued operations, the share of profits and losses of associates and joint ventures (net of related tax and non-controlling interests), one-off adjustments for the impairment and fair value changes of certain assets and liabilities (net of related tax and non-controlling interests), fair value losses/(gains) of current equity investments (net of related tax and non-controlling interests), share-based payments (net of related tax and non-controlling interests), effective interest expenses and exchange (gain)/loss of the convertible bond debt component, adjusted non-HKFRS profit attributable to the owners of the parent was approximately RMB3.46 billion, an increase of approximately 33.5% over last year. The Group's liquidity remains strong, with total fund reserve at approximately RMB24.11 billion, including cash and bank balances classified under current assets of approximately RMB9.57 billion, bank deposit classified under non-current assets of approximately RMB9.37 billion, and the wealth management products of approximately RMB5.17 billion in aggregate.The Board of Directors has recommended a final dividend payment of HK4 cents per share (2023: HK3 cents). Together with the interim dividend of HK3 cents already paid, the total dividend for the year amounted to HK7 cents (2023: HK5 cents).Sales: Robust sales system continues to drive results  Achieves positive revenue growth for  generic drugsOn the strong foundation its generic drug business provides, the Group has comprehensively promoted innovation and transformation. The innovative products have kept boosting sales growth, with share of revenue climbing year after year. Revenue from innovative products amounted to RMB12.06 billion, up by 21.9% year-on-year, and accounted for 41.8% of the Group's total revenue.During the year, the sales of oncology medicines amounted to approximately RMB10.73 billion, representing approximately 37.2% of the Group’s revenue. The sales of surgery/analgesia and liver disease amounted to approximately RMB4.46 billion and RMB3.44 billion, respectively, representing approximately 15.4% and 11.9% of the Group's revenue, respectively. In addition, sales contributions from various areas such as respiratory, cardio-cerebral vascular medicines and others have continued to contribute to the Group's revenue. Among them, the sales of respiratory and cardio-cerebral vascular medicines accounted for approximately 10.9% and 7.5% of the Group's revenue, respectively.R&D: Pushes at full force innovative product development  Actively applies for various patentsThe Group has continued to focus its R&D efforts on new medicines in the four therapeutic areas of oncology, liver diseases, respiratory and surgery/analgesia. As at the end of the reporting period, the Group had 70 innovative products under development, including 39 oncology products, 7 liver disease products, 13 respiratory products, and 6 surgery/analgesia products, and 5 other products. In addition, the Group had 65 generic drug products in development.The Group also attaches tremendous importance to the protection of intellectual property rights and encourages its member enterprises to file patent applications in order to enhance the Group’s core competitiveness. During the reporting period, the Group filed 1,069 new patent applications and received 349 patent invention approvals. As at the end of the reporting period, the Group had accumulated 5,082 effective patents and patent applications and obtained 1,958 patent invention approvals.Prospects: Focuses on core business and innovation  Continues to promote dual-pronged approach in implementing globalization strategyThe Chinese pharmaceutical market has occupied a key position in the global pharmaceutical industry due to its huge volume and increasing market demand. In addition, as a strategic industry closely linked to the national economy and people’s livelihood, the pharmaceutical industry receives key support from national policies and incentives. Meanwhile, a series of policies is expected to broaden the pricing flexibility of innovative drugs, improve their accessibility, and create a wider market prospect for such drugs.Committed to its vision “to be a leading global pharmaceutical company through delivering innovative therapies for patients”, the Group has adhered to comprehensive innovation, stepped up its R&D investment, and continued to strengthen its internal R&D capabilities. It has now built a comprehensive pipeline and product portfolio. At the same time, the Group has vigorously promoted business development and strategic cooperation, striving to become the best partner for global pharmaceutical and biotechnology enterprises.At present, the Group has entered the harvest period of its innovative development. It is expected that by 2027, the number of innovative products launched to the market will exceed 30, with revenue from innovative products accounting for over 55% of total revenue. This will further strengthen the Group’s dominant position in the four main therapeutic areas and provide strong impetus for the future sustainable growth. In addition, the Group has advanced its digitalization strategy with artificial intelligence (AI) as the core driving force. It has finished locally deploying cutting-edge AI models including DeepSeek and ChatGPT, and optimized key business such as cross-departmental collaboration, thereby significantly improving operational efficiency.Meanwhile, the Group adopts its dual-pronged globalization strategy to accelerate innovation and development. The Group will bring global pharmaceutical innovations to China to benefit Chinese patients, while also expanding its presence in international markets to target unmet clinical needs worldwide.Looking ahead, the Group will further focus on its core business and innovation, and continue to improve R&D efficiency and quality in the four major therapeutic areas. It will also actively accelerate the deployment for globalization of its business to drive rapid business growth and steady performance improvement, and contribute to the development of the global pharmaceutical industry.About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited is a leading Chinese pharmaceutical company continuing to invest in Oncology, Liver Diseases, Respiratory and Surgery/Analgesia, exploring innovative therapies to improve the lives of patients. The company has strong manufacturing capabilities and broad patient access across China. Sino Biopharmaceutical Limited is committed to bring innovation to address unmet healthcare needs globally. The company was listed on the Hong Kong Stock Exchange in 2000, and was selected as a component of the MSCI Global Standard Index in China in 2013; In 2018, it was selected as a constituent stock of Hang Seng Index; In 2020, it was selected as a constituent stock of Hang Seng Connect Biotech 50 Index and the Hang Seng China (Hong Kong Listed) 25 Index. The company has been listed in the “Top 50 Global Pharmaceutical Enterprises” published by the authoritative American magazine Pharmaceutical Manager for six consecutive years, and has been rated as the “Top 50 Best Companies in Asia Pacific” by Forbes (Asia) for three consecutive years.For more information, please visit: www.sinobiopharm.com Copyright 2025 ACN Newswire via SeaPRwire.com.

祖龙娱乐发布2024年全年业绩

财务摘要︰- 2024年收益为人民币1,141.1百万元,较2023年同期增长25.6%。其中,综合游戏发行及运营业务收益同比增长45.9%至人民币1,035.0百万元,占总收益的90.7%。- 2024年毛利为人民币826.0百万元,较2023年同期增长27.0%,毛利率为72.4%,与去年同期保持基本一致。- 2024年研发开支同比减少8.6%至人民币532.1百万元,销售及营销开支增加至人民币565.0百万元,主要由于报告期内《龙族:卡塞尔之门》在中国大陆上线以及《以闪亮之名》持续进行运营推进所致。- 2024年经调整亏损净额较2023年同期收窄4.6%至人民币270.0百万元。营运摘要︰- 截至2024年全年业绩公告发布之日,集团在逾170个地区市场推出23款精品手游,支持14种语言的多个地区版本,已上线游戏的全球累计注册用户数超过2亿人,全球累计总流水超过人民币220亿元。  - 超自由时尚女性向手游《以闪亮之名》自上线以来,十余次以强劲之姿跻身中国大陆iOS游戏畅销榜前十名。伴随两周年庆活动序幕拉开,游戏不但于2025年3月4日跃居iOS游戏畅销榜第八,更是凭借高质量精准呈现的大屏效果,高居iPad畅销榜第二。截至2024年12月31日,《以闪亮之名》的全球累计注册用户数超过2,000万。  - 策略卡牌类游戏《龙族:卡塞尔之门》于2024年9月在中国大陆地区正式上线,上线首日即登顶iOS应用商店游戏免费榜并持续霸榜一周,且连续数日冲入游戏畅销榜前十名,成为祖龙娱乐又一款首月流水超过人民币1亿元的自主发行产品。  - 经典MMORPG手游《龙族幻想》以及回合制MMORPG手游《梦幻诛仙》持续实施多维度运营策略,有效实现了产品的长线平稳运营,保持了收益的持续稳定。- 为打造不同类型及多样化的游戏组合,集团预期于2025年至2027年期间在全球各地推出8款包括MMORPG、放置PRG、策略卡牌及其他类型的游戏产品,其中包括一款由虚幻引擎4打造的中国风修真题材放置RPG手游《踏风行》以及一款回合制MMORPG游戏项目代号:逍遥。香港, 2025年3月21日 - (亚太商讯 via SeaPRwire.com) - 祖龙娱乐有限公司("祖龙娱乐"或"公司",连同其附属公司,统称"集团",股份代号:9990.HK)公布其截至2024年12月31日止年度("报告期内")之经审核年度业绩。2024年,祖龙娱乐录得收益人民币1,141.1百万元,较截至2023年同期人民币908.5百万元增加25.6%,主要由于报告期内《龙族:卡塞尔之门》在中国大陆上线及《以闪亮之名》持续发力所致;其中,综合游戏发行及运营业务收益较截至2023年同期同比增长45.9%至人民币1,035.0百万元,占总收益的90.7%。2024年,集团毛利为人民币826.0百万元,较2023年同期同比增长27.0%,毛利率为72.4%,与去年同期保持基本一致。报告期内,集团研发开支同比减少8.6%至人民币532.1百万元,销售及营销开支增加至人民币565.0百万元,主要由于报告期内《龙族:卡塞尔之门》在中国大陆上线及《以闪亮之名》推广及广告开支增加所致。受上述因素综合影响,2024年集团经调整亏损净额较2023年同期收窄4.6%至人民币270.0百万元。《以闪亮之名》验证长线运营实力,新游上线助力产品赛道拓展以公司新一代女性制作策划团队为核心研发的超自由时尚女性向手游《以闪亮之名》,自上线以来十余次以强劲之姿跻身中国大陆iOS游戏畅销榜前十名,其2025年1月的单月利润更是创下该游戏的历史新高。伴随两周年庆活动序幕拉开,游戏不但于2025年3月4日跃居iOS游戏畅销榜第八,更是凭借高质量精准呈现的大屏效果,高居iPad畅销榜第二,当日流水攀升至一周年庆以来的峰值。2024年,游戏持续进行高质量的迭代更新,与中国邮政、上海海昌海洋公园、沙漠邮局等开展联动活动;更融入了蜀绣、泉州提线木偶戏、德化白瓷、京剧、柯尔克孜族刺绣、藏羌织绣等中国非物质文化遗产定制内容。此外,宠物系统凭借其单只可达三千万根毛发的极致毛流感和独特的渲染及染色工艺,叠加多样亲宠玩法,一经上线即获得玩家广泛关注。未来游戏还将解锁大地图以及模拟经营等更多新玩法,为玩家带来更丰富多元的游戏体验。《以闪亮之名》官方微博已累计获得超过1,700万个转评赞,TapTap平台评分持续高达8.9分。截至2024年12月31日,《以闪亮之名》的全球累计注册用户数超过2,000万。由虚幻引擎4打造的、根据《龙族》系列小说和动画改编开发的策略卡牌类游戏《龙族:卡塞尔之门》,于2024年9月12日在中国大陆地区正式上线。上线首日即登顶iOS应用商店游戏免费榜并持续霸榜一周,且连续数日冲入游戏畅销榜前十名,成为公司又一款首月流水超过人民币1亿元的自主发行产品。该游戏于2024年11月26日携手金坛刻纸推出"凭秋剪意"联动活动,将非遗瑰宝独特魅力融合游戏元素展现在玩家面前。值得关注的是,对于自上线以来已分别运营超过5年和8年的由虚幻引擎4驱动的MMORPG手游《龙族幻想》以及回合制MMORPG手游《梦幻诛仙》,凭借多维度的运营策略持续提升了用户体验。这些举措有效实现了产品的长线平稳运营,保持了收益持续稳定。多元游戏储备丰富产品矩阵,"研运一体"战略延长生命周期为打造不同类型及多样化的游戏组合,集团预期于2025年至2027年期间在全球各地推出8款包括MMORPG、放置RPG、策略卡牌及其他类型的游戏产品。其中,由虚幻引擎4打造的中国风修真题材放置RPG手游《踏风行》于2025年3月开启了新一轮付费测试,并预计将于2025年上半年在中国大陆地区正式上线,该游戏计划主要采用自主发行方式。另一款融合国风和卡通美学的回合制MMORPG游戏项目代号:逍遥,计划于2025年对外开展测试。此外,改编自《龙族》系列小說,并依托虚幻引擎5打造的开放世界MMORPG+游戏项目代号:Odin正在有序开发中。日后,随着产品类型由MMORPG、SLG、女性向、策略卡牌扩张至放置RPG等多品类和丰富多样的风格,及持续完善"研运一体"的有机模式,预期公司游戏的生命周期将进一步延长,这将对集团的收益作出更稳定及持续的贡献。技术创新驱动产品力提升,社会责任引领企业长期价值创新是祖龙娱乐持续发展的核心动力,技术是公司不断提升竞争力的重要支撑。作为游戏领域的先锋,祖龙娱乐率先将全球领先的虚幻引擎技术引入移动游戏开发,不断突破技术边界,探索未知的可能性。集团不断在大语言模型(Large Language Model,LLM)方面研究探索,并迅速开展在游戏产品内接入及本地化部署DeepSeek的工作。同时,公司的技术团队基于公司产品实际需求正在自主开发能够在游戏内嵌入高智能化NPC的模型架构,在控制成本的基础上更快实现智能化技术的升级与玩家体验的提升。此外,集团还在不断积极推进AIGC(Artificial Intelligence Generated Content)与UGC(User Generated Content)融合性创作的前沿尝试,力争让玩家能够更便捷地在游戏内进行创意表达。正是这种对技术的执着追求与创新实践,让祖龙娱乐屹立于行业的前沿。与此同时,作为行业中负责任且有温度的游戏公司,祖龙娱乐积极践行社会责任,笃定躬行社会公益,成功开展了"鸿鹄筑梦公益计划"、"龙行公益"等活动,在文化创新、产教融合等方面取得了可圈可点的表现。展望未来,作为中国领先的游戏研发与运营厂商,祖龙娱乐将继续走在游戏行业技术探索前沿,继续坚持精品化、多品类、研运一体、全球化的核心战略,持续开发各品类行业领先的精品游戏,在文娱领域持续探索和思考,对市场及用户的定位、玩家喜好、推广策略等挖掘更深刻的认识,脚踏实地,勇敢出发,为全球玩家创造卓越的在线娱乐体验。关于祖龙娱乐有限公司祖龙娱乐是中国手游行业的开拓者,专注于开发优质MMORPG、SLG、女性向、策略卡牌及其他类型的手游,开发优质手游的实力屡经验证,且注重核心游戏性体验品类的持续深耕。截至目前,祖龙娱乐在逾170个地区市场共推出23款精品手游,支持14种语言的多个地区版本,所提供的高质量的多元游戏组合拥有良好的市场声誉。 Copyright 2025 亚太商讯 via SeaPRwire.com.

超市及便利店连锁运营商 江苏宏信超市H股全球发售

发售摘要:- 香港公开发售将于2025年3月26日(星期三)中午十二时正(白表eIPO服务申请于上午十一时三十分)截止;- 发行价范围:2.50港元至3.00港元;- 每手1,000股;- 最大集资净额约1.177亿港元(于任何超额配股权获行使前);- 预期股份在2025年3月31日(星期一)于香港联交所主板开始买卖;- 绰耀资本有限公司为独家保荐人。香港, 2025年3月21日 - (亚太商讯 via SeaPRwire.com) - 江苏宏信超市连锁股份有限公司("公司",股份代号:2625)今日宣布全球发售及于香港联合交易所有限公司("香港联交所")主板上市之计划。江苏宏信超市连锁股份有限公司是一家粮油批发商,总部设在扬州,主要集中在苏中地区以"宏信龙"品牌经营超市及便利店零售业务。根据行业报告,按销售额计,公司于2023年在扬州超市运营商中排名第二,市场份额约为9.1%,及按销售额计,公司于2023年在江苏中部地区的超市运营商中排名第五,市场份额约为2.3%,及按2023年的销售额计,于江苏省超市营运商中排名第20位左右,市场份额约为0.4%。江苏宏信超市连锁股份有限公司计划发售的股份数目为53,562,000股(视乎超额配售权行使与否而定),其中,香港发售股份数目为5,357,000股(可予重新分配),国际发售股份数目为48,205,000股(可予重新分配及视乎超额配售权行使与否而定)。发售价范围2.50港元至3.00港元,每手买卖单位1,000股。是次香港公开发售于2025年3月21日(星期五)开始,并预期于2025年3月26日(星期三)中午十二时正(白表eIPO服务申请于上午十一时三十分)截止。公司H股预期将在2025年3月31日(星期一)于香港联交所主板开始买卖。假设超额配股权完全不获行使,倘发售价定为每股3.00港元(即发售价范围的上限),则全球发售的所得款项净额将增至约1.177亿港元。公司拟将全球发售的所得款项净额用作下列用途:- 约30.9%将用作开设新零售店铺,其中包括门店翻新,购买货价,购买冷藏设施、照明、空调、闭路电视监控系统及POS系统及用于安装消防安全系统。- 约41.2%将用作建立新配送中心,其中包括收购地块用于建设新配送中心,新配送中心的建设及购置货架、灯具及附属设施以及安装消防安全系统。- 约26.8%将用作建立新的餐食中央厨房,其中包括建设新中央厨房,采购机器及设备,购置及安装消防安全系统、通风系统、冷藏设施、公用事业、空调、闭路电视监控系统及配套设施及购买额外车辆,以向客户配送餐食。- 约1.1%将用于增强ERP系统及基础设施系统,以提高运营效率。公司已成功引入基石投资者Top Legend SPC,其同意认购H股为可按发售价(包括经纪佣金、证监会交易征费及联交所交易费)认购总额为500万美元的数目,禁售期为六个月。绰耀资本有限公司为独家保荐人。绰耀资本有限公司及民银证券有限公司为联席整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人。建银国际(控股)有限公司为联席全球协调人、联席账簿管理人及联席牵头经办人。招银国际融资有限公司、盈立证券有限公司、星河证券有限公司、艾德证券期货有限公司、创升证券有限公司、长桥证券(香港)有限公司为其他联席账簿管理人及联席牵头经办人。 Copyright 2025 亚太商讯 via SeaPRwire.com.

Q2 Metals Intercepts 179.6 Metres of Continuous Spodumene Pegmatite in Large Step-Out at the Cisco Lithium Project in Quebec, Canada

Highlights:Drill hole CS25-027 encountered seven (7) spodumene pegmatite intervals, with the widest continuous interval of 179.6 metres (m), followed by two additional intervals of 58 m and 91.8 m of continuous spodumene pegmatite.Drill hole CS25-024/24A intersected a total of six (6) individual spodumene pegmatite intervals, with the widest continuous interval of 39.5 m.Drill hole CS25-025 encountered nine (9) spodumene pegmatite intervals, with the widest continuous interval of 20.4 m.Drill hole CS25-026 encountered 10 spodumene pegmatite intervals, with the widest continuous interval of 21.2 m.Assays are pending on the approximately 2,570 m of core drilled in the first four (4) holes completed to date in the winter drill campaign at the Cisco Project.Drilling continues with step outs to both the east and south.Vancouver, BC, Mar 19, 2025 - (ACN Newswire via SeaPRwire.com) - Q2 Metals Corp. (TSXV:QTWO)(OTCQB:QUEXF)(FSE:458) ("Q2" or the "Company") is pleased to announce the completion of the first four holes of the winter 2025 expansion drilling campaign at the Company's Cisco Lithium Project (the "Project" or the "Cisco Project"), located within the greater Nemaska traditional territory of the Eeyou Istchee James Bay, Quebec, Canada.Multiple wide intercepts of continuous spodumene pegmatite were encountered within a total of 2,570 metres of drilling completed to date, significantly increasing the extent of previously encountered mineralization (see Figure 1). All holes intercepted pegmatites with visual indications of spodumene mineralization identified."We are extraordinarily pleased with these initial findings from our winter campaign which has not only produced one of our top holes in terms of the total amount of spodumene pegmatite per hole, but continues to provide important information about the mineralization at Cisco," said Q2 Metals President and CEO Alicia Milne. "We are continuing to explore the robust and continuous nature of Cisco's mineralization with additional step outs to both the south and east.""The first four holes of the winter drill program have expanded the strike length of the mineralized system and has confirmed that it continues to extend to the south, further increasing Cisco's potential scale," said Q2 VP Exploration Neil McCallum. "Hole-27, with 179.6 metres of continuous spodumene pegmatite, plus an additional 58 and 91.8 metres of continuous spodumene pegmatite, lends further support to our theory of a south-trending mineralized system, which now extends over a kilometre."Figure 1. Map of Drilling area, Cisco ProjectWinter 2025 Exploration Program OverviewThe current 2025 Winter Program is targeting 6,000 - 8,000 m of drilling with 200 - 400 m step outs with the primary objective of expanding upon the exceptionally promising drill results from the inaugural 2024 campaign, which included:Drill hole CS-24-018 - 215.6 m at 1.69% Li 2 O;Drill hole CS-24-021 - 347.1 m at 1.35% Li 2 O; andDrill hole CS-24-023 - 188.6 m at 1.56% Li 2 O.One diamond drill rig tested to the southwest of drill hole CS-24-023 to define the strike length:Drill hole CS25-025 was collared approximately 275 m south of hole CS24-023; andDrill hole CS25-027 is located 200 m southeast of hole CS25-025.This fence of holes was designed to test the southward extension of the large and wide mineralized system and did so successfully with hole CS25-027's widest continuous interval of 179.6 m of spodumene-bearing pegmatite.One diamond drill rig tested to the east of drill holes CS-24-018 and CS-24-021 to define potential additional parallel pegmatite zones:Drill hole CS25-024A was drilled as a follow-up to hole CS25-024 which was lost due to difficult drilling conditions. It was collared approximately 400 m southeast of hole CS24-022; andDrill hole CS25-026 was collared approximately 400 m from CS24-021 and 285 m north of hole CS25-024A.Drilling remains ongoing, with step outs continuing both east and south.Figure 2. Drill Rig Locations at the Cisco Lithium ProjectSummary of Spodumene-Bearing Pegmatite IntervalsThe pegmatite intervals (greater than 2 m) of drill holes CS-25-024A to 027 are reported below in detail (Table 1).Table 1. Summary of Spodumene-Pegmatite Intervals, Cisco ProjectThe mineralized intervals in all the holes are not necessarily representative of the true width and the modelled pegmatite zones are being refined with every additional hole.Cautionary Statement: The presence of pegmatites does not confirm the presence of lithium (spodumene or other lithium minerals). Pegmatites are fractionated coarse grained igneous rocks commonly associated with lithium mineralization; however, many pegmatites do not contain mineralization. The presence of any mineralization can only be confirmed with assaying.The geological team has completed the core cutting and logging of holes CS25-024/24A to CS25-027 and the samples have been dispatched to the SGS Canada preparation laboratory located in Val-d'Or, QC for mineral analysis to confirm the presence of lithium.Figure 3. Core from the Current Drill Program at Cisco Lithium ProjectSampling, Analytical Methods and QA/QC ProtocolsAll drilling was conducted using diamond drill rig with NQ sized core and all drill core samples are shipped to SGS Canada's preparation facility in Val D'Or, Quebec, for standard sample preparation (code PRP92) which includes drying at 105°C, crushing to 90% passing 2 mm, riffle split 500 g, and pulverize 85% passing 75 microns. The pulps are then shipped by air to SGS Canada's laboratory in Burnaby, BC, where the samples are homogenized and subsequently analyzed for multi-element (including Li and Ta) using sodium peroxide fusion with ICP-AES/MS finish (code GE_ICM91A50). The reported Li grade will be multiplied by the standard conversion factor of 2.153 which results in an equivalent Li 2 O grade. Drill core was saw-cut with half-core sent for geochemical analysis and half-core remaining in the box for reference. The same side of the core was sampled to maintain representativeness.A Quality Assurance / Quality Control (QA/QC) protocol following industry best practices was incorporated into the sampling program. Measures include the systematic insertion of quartz blanks and certified reference materials (CRMs) into sample batches at a rate of approximately 5% each. Additionally, analysis of pulp-split and reject-split duplicates was completed to assess analytical precision. The QP has verified the QA/QC results of the analytical work.Drill Hole Collar InformationThe summary of drill holes completed to date, including basic location and dip/azimuth is detailed below (Table 2).Coordinates are in UTM NAD83, zone 18All holes are NQ-Size diamond drill coreAzimuth and dip are reported as planned, and will deviate down-holeReported hole depths are subject to minor changes based on final core observationsTable 2. Summary of Drill Hole Collar Information, Cisco Project (CS25-024-027)Upcoming EventsIgnite Investment SumitThe Company will be attending the Ignite Investment Summit in Hong Kong March 26-27, 2025.For more information, click here.Future Facing Commodities ConferenceThe Company will be attending and exhibiting at the Tribeca Future Facing Commodities 2025 Conference in Singapore on April 1-3, 2025.For more information, click here.About Q2 Metals CorpQ2 Metals is a Canadian mineral exploration company focused on the Cisco Lithium Project located within the greater Nemaska traditional territory of the Eeyou Istchee, James Bay, Quebec, Canada where drilling is currently underway.The Cisco Project is comprised of 767 claims, totaling 39,389 hectares. The main mineralized zone is just 6.5 kilometres ("km") away from the Billy Diamond Highway and transects the Project. The town of Matagami, which features direct rail link to much of James Bay, is approximately 150 km to the south.Cisco has district-scale potential with an already identified mineralized zone and 2024 discovery drill results that include:120.3 metres at 1.72% Li 2 O (hole CS-24-010);215.6 metres at 1.69% Li 2 O (hole CS-24-018);347.1 metres at 1.35% Li 2 O (hole CS-24-021); and188.6 metres at 1.56% Li 2 O (hole CS-24-023)The Cisco Project is situated along the Frotet Evans Greenstone Belt, comprised of a volcanic package dominated by mafic to felsic metavolcanic rocks, of the southern James Bay Lithium District, the same belt that hosts the Sirmac and Moblan lithium deposits, located 130 km and 180 km away, respectively.FOR FURTHER INFORMATION, PLEASE CONTACT:Alicia Milne, President & CEO, Alicia@Q2metals.comJason McBride, Corporate Communications, Jason@Q2metals.comChris Ackerman, Corporate Communications, Chris@Q2metals.comTelephone: 1 (800) 482-7560, E-mail: info@Q2metals.com www.Q2Metals.comClick to follow us online:X, LinkedIn, Facebook, and InstagramQualified PersonNeil McCallum, B.Sc., P.Geol, a registered permit holder with the Ordre des Géologues du Québec and Qualified Person as defined by NI 43-101 ("QP"), has reviewed and approved the technical information in this news release. Mr. McCallum is a director and VP Exploration for Q2.Forward-Looking StatementsThis news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian legislation. Forward-looking statements are typically identified by words such as: "believes", "expects", "anticipates", "intends", "estimates", "plans", "may", "should", "would", "will", "potential", "scheduled" or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. Accordingly, all statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, any statements or plans regard the geological prospects of the Company's properties and the future exploration endeavors of the Company. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Forward-looking statements are based on a number of material factors and assumptions.Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated in such forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date specified in such statement. Forward-looking statements in this news release include, but are not limited to, drilling results on the Cisco Project and inferences made therefrom, the potential scale of the Cisco Project, the focus of the Company's current and future exploration and drill programs, the scale, scope and location of future exploration and drilling activities, the Company's expectations in connection with the projects and exploration programs being met, the Company's objectives, goals or future plans, statements, exploration results, potential mineralization, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from those in forward-looking statements include failure to obtain necessary approvals, variations in ore grade or recovery rates, changes in project parameters as plans continue to be refined, unsuccessful exploration results, changes in project parameters as plans continue to be refined, results of future resource estimates, future metal prices, availability of capital and financing on acceptable terms, general economic, market or business conditions, risks associated with regulatory changes, defects in title, availability of personnel, materials and equipment on a timely basis, accidents or equipment breakdowns, uninsured risks, delays in receiving government approvals, unanticipated environmental impacts on operations and costs to remedy same. Readers are cautioned that mineral exploration and development of mines is an inherently risky business and accordingly, the actual events may differ materially from those projected in the forward-looking statements. Additional risk factors are discussed in the section entitled "Risk Factors" in the Company's Management Discussion and Analysis for its recently completed fiscal period, which is available under Company's SEDAR profile at www.sedarplus.ca.Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.SOURCE: Q2 Metals Corp. Copyright 2025 ACN Newswire via SeaPRwire.com.

Jiangsu Horizon Chain Supermarket, a Supermarket and Convenience Store Chain Store Operator, Announces Its Global Offering and Listing of H Shares on the Main Board of the Hong Kong Stock Exchange

Highlights of the Global Offering:- The Hong Kong Public Offering is expected to close at 12:00 noon (at 11:30 a.m. for completing electronic applications under the White Form eIPO service) on Wednesday, 26 March 2025;- Offer Price Range: HK$2.50 to HK$3.00 per Share;- The Shares will be traded in board lots of 1,000 Shares each;- Maximum net proceeds will be approximately HK$117.7 million (before any exercise of the Over-allotment Option);- Dealings in the Shares on the Main Board of the Hong Kong Stock Exchange are expected to commence on Monday, 31 March 2025;- Red Solar Capital Limited is the Sole Sponsor.HONG KONG, Mar 21, 2025 - (ACN Newswire via SeaPRwire.com) - Jiangsu Horizon Chain Supermarket Company Limited (the “Company”, stock code: 2625) today announces its Global Offering and the listing of Shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).Jiangsu Horizon Chain Supermarket Company Limited is a wholesaler of grains and oil headquartered in Yangzhou, with retail operations of supermarket and convenience stores focusing on the central region of Jiangsu Province under the brand 'Hongxinlong'. According to the Industry Report, the Company ranked second among supermarket operators in Yangzhou in terms of sales in 2023 with a market share of approximately 9.1%, the fifth among supermarket operators in the central region of Jiangsu Province in terms of sales in 2023 with a market share of approximately 2.3%, and around the twentieth among supermarket operators in Jiangsu province in terms of sales in 2023 with a market share of approximately 0.4%.Jiangsu Horizon Chain Supermarket Company Limited plans to offer an aggregate of 53,562,000 Shares (subject to Over-allotment Option) under the Global Offering, of which 48,205,000 Shares (subject to reallocation and the Over-allotment Option) will be offered by way of International Placing, and 5,357,000 Shares (subject to reallocation) will be offered in the Hong Kong Public Offering. The Offer Price will not be more than HK$3.00 per Share and is currently expected to be not less than HK$2.50 per Share, with the board lot size of 1,000 sharesThe Hong Kong Public Offering commenced on Friday, 21 March 2025 and is expected to close at 12:00 noon (at 11:30 a.m. for completing electronic applications under the White Form eIPO service) on Wednesday, 26 March 2025. Dealings in H Shares on the Stock Exchange are expected to commence on Monday, 31 March 2025.Assuming the Over-allotment Option is not exercised at all, if the Offer Price is set at HK$3.00 per Share (being the high end of the Offer Price range), the net proceeds from theGlobal Offering will increase to approximately HK$117.7 million. The Company intends to apply the net proceeds for the following purposes:- Approximately 30.9% will be used for the opening of new Retail Stores, including store renovation, purchase of shelves, purchase of cold storage facilities, lightings, air-conditioning, CCTV surveillance system and POS system and installation of fire safety system.- Approximately 41.2% will be used for establishing a new distribution centre including acquiring a parcel of land for the construction of the New Distribution Centre, acquiring shelves, lightings and ancillary facilities and installing fire safety system.- Approximately 26.8% will be used for establishing a new central kitchen, including the construction of the New Central Kitchen, acquiring machines and equipment, acquiring and installing fire safety system, ventilation system, cold storage facilities, utilities, air-conditioning, CCTV surveillance system and ancillary facilities, and acquiring additional vehicles for the delivery of meals to the customers.- Approximately 1.1% will be used for enhancing the ERP system and infrastructure systems to improve operational efficiency.The Company has successfully procured cornerstone investor Top Legend SPC, Top Legend has agreed to subscribe for such number of H Shares which may be subscribed with an aggregate amount of US$5.0 million at the Offer Price (including brokerage, SFC transaction levy and Stock Exchange trading fee). The lock-up period shall last for a duration of six months.Red Solar Capital Limited is the Sole Sponsor. Red Solar Capital Limited and CMBC Securities Company Limited are the Joint Overall Coordinators, Joint Global Coordinators, Joint Bookrunners, and Joint Lead Managers. CCB International Capital Limited is the Joint Global Coordinators, Joint Bookrunners, and Joint Lead Managers. CMB International Capital Limited, uSMART Securities Limited, Star River Securities Limited, Eddid Securities and Futures Limited, Innovax Securities Limited, and Long Bridge HK Limited are the other Joint Bookrunners and Joint Lead Managers. Copyright 2025 ACN Newswire via SeaPRwire.com.

CTF Life Title-sponsors: ‘Fencing Plus’ Training Programme by Kai Tak Sports Initiative

HONG KONG, Mar 21, 2025 - (ACN Newswire via SeaPRwire.com) - “Fencing Plus” Training Programme, title-sponsored by CTF Life and organised by Kai Tak Sports Initiative, aims to identify children aged 6 to 10 with potential in fencing through structured selection and training process. The programme seeks to nurture the next generation of elite fencing athletes, who will represent Team Hong Kong, China, to become future world champions while promoting the culture of “Sports for All” and enhancing professionalism. Applications are now open (starting 18 Mar), with the goal of recruiting 600 promising fencing students.Two-Year Structured Training Led by Hong Kong Fencing Team Team ManagerThe "Fencing Plus" Training Programme (the Programme), organised by Kai Tai Sports Initiative—the community project of Kai Tak Sports Park—and title-sponsored by CTF Life for the first time this year, aims to select students with fencing potential through a scientific approach and provide them with nearly two years of structured training. In the later stages of the Programme, students will have the opportunity to compete against fencers from different countries and regions, honing their skills while embracing the spirit of true sportsmanship and overcoming challenges. Additionally, CTF Life will support selected children from underprivileged families from Kowloon East to participate in the programme.The Programme will be led by Antonio Lam, Team Manager of Hong Kong Fencing Team, Asian Games Double Bronze Medalist and Olympic Games representative for the Hong Kong Fencing Team, will serve as the Head Coach of the Programme. He will guide a team of professional coaches to provide tailored instructions, analyse the potential of students, and deliver an extensive training framework, inspiring a spirit of sportsmanship in every participant.First Stage Selection Begins in May: No Fencing Experience RequiredThe first stage of the Programme, the "Fencing Plus" Training Programme Selection Day, will be held on 4 May, 2025 (Sunday) from 10:00 a.m. to 5:00 p.m. at the Kai Tak Arena. On that day, children will participate in a full-day interactive test assessing their physical fitness ability, coordination, and reaction assessments. No prior fencing experience is required to participate.From now until 31 March, 2025, guardians can submit application for their children by registering to become members of CTF Life‧CIRCLE and donating HK$100 to the "Kai Tai Sports Initiative Foundation", which will be used to support on community activities. Qualified students will undergo structured training in basic and advanced stages. The programme features exclusive quotas for CTF Life‧CIRCLE members, while Diamond and Gold members can enjoy priority enrolment and participation, accessing to premium experiences.Progressive Training to Unlock Potential: Leading "MyFuture Fencers" to Compete InternationallySelected students will undergo basic and advanced training stages, after which they will have the opportunity to participate in the CTF Life “Fencing Plus” Cup. Outstanding performers will be selected for an 18-month elite training and the chance to get into Hong Kong Under-14 professional fencing training scheme.  - Stage Two: Basic Training, with a commemorative certificate upon meeting the required standard- Stage Three: Advanced Training, with a commemorative certificate upon meeting the required standard- Stage Four: CTF Life “Fencing Plus” Cup, with registration fee for selected participants from the programme will be fully sponsored by CTF Life- Stage Five: Elite Training Programme to nurture future sports starsRegistration Link:https://lifepillars.ctflife.com.hk/pillars/edutainmentThe content and schedule of the above programme are subject to change without prior notice.About CTF LifeChow Tai Fook Life Insurance Company Limited (“CTF Life”) is proud of its rich, 40-year legacy in Hong Kong. CTF Life is a wholly-owned subsidiary of CTF Services Limited and one of the most well-established life insurance companies in Hong Kong. As a member of Chow Tai Fook Enterprises Limited, CTF Life consistently strengthens its collaboration with the diverse conglomerate of the Cheng family (“Chow Tai Fook Group” or “the Group”) to support customers and their loved ones in navigating life’s journey with personalised planning solutions, lifelong protection and diverse lifestyle experiences. By leveraging the Group’s robust financial strength and strategic investments across the globe, CTF Life aspires to become a leading insurance company in Asia while continuously creating value beyond insurance. Copyright 2025 ACN Newswire via SeaPRwire.com.

中国生物制药(1177.HK)公布2024全年业绩

财务摘要 截至12月31日止年度 人民币2024年2023年变动    人民币亿元人民币亿元%收入288.7262.0+10.2%毛利率(%)81.5%81.0%+0.5 百分点销售及管理费用占收入比例(%)*42.1%42.2%-0.1百分点研发费用占收入比例(%)17.6%16.8%+0.8百分点本年度盈利63.651.0+24.9%归属于母公司持有者应占盈利**35.023.3+50.1%经调整非《香港财务报告准则》归母净利润***34.625.9+33.5%基于归属于母公司持有者之经调整非《香港财务报告准则》归母净利润计算之每股基本盈利(人民币分)18.9013.97+35.3%创新产品收入****120.698.9+21.9%占收入比例(%)41.8%37.8% 新产品收入*****100.980.5+25.4%占收入比例(%)35.0%30.7% 每股股息(港仙)7.05.0+40.0%-中期3.02.0+50.0%-末期4.03.0+33.3%*销售及分销成本加行政费用除以收入**归属于母公司持有者盈利同比显著增长主要受惠于本年度收入明显增长及录得出售附属公司收益***指撇除已终止经营业务、若干非现金项目以及联营公司及合营公司之盈利及亏损之影响后的归属于母公司持有者基本盈利****收入为销售额扣除销售折扣,创新产品包含创新药及生物类似药*****五年内上市的产品重点成果肿瘤创新药- 福可维(盐酸安罗替尼胶囊)目前已获批七个适应症。三项新适应症已向中国国家药品监督管理局药品审评中心(「CDE」)递交上市申请,另有三项新适应症的关键性临床试验已取得阳性结果,集团将于近期向CDE递交新增该等适应症的上市申请。此外,安罗替尼还有多项新适应症的临床研究正在III期,包含一线非鳞状非小细胞肺癌、一线结直肠癌等,预计将在未来几年逐步递交上市申请。- 亿立舒(艾贝格司亭)注射液通过三项全球多中心、随机、对照研究的关键性III期临床试验,与临床上常用的短效升白药和长效升白药进行了对比,证明了其疗效和安全性。艾贝格司亭于2023年成功纳入国家医保目录,并在2024年加速放量,成为集团收入增长的重要贡献品种。- 安方宁(格索雷塞片)是一款新型、高效的KRAS G12C抑制剂,于2024年11月获得NMPA的上市批准,用于治疗至少接受过一种系统性治疗的KRAS G12C突变型的晚期非小细胞肺癌。集团将深入挖掘格索雷塞的多适应症潜力,有望将其打造为肿瘤领域的又一款重磅产品。- 安倍斯(贝伐珠单抗注射液)、得利妥(利妥昔单抗注射液)、赛妥(注射用曲妥珠单抗)和帕乐坦(帕妥珠单抗注射液)分别于2023年2月、2023年5月、2023年7月和2024年12月获得NMPA的上市批准。该等生物类似药在2024年快速放量,加速了集团的收入增长。肝病创新药- 天晴甘美(异甘草酸镁注射液)是第四代甘草酸制剂,目前已获批3个适应症:慢性病毒性肝炎、急性药物性肝损伤和改善肝功能异常。异甘草酸镁是全球第一个99.9%的纯化体甘草酸,具有肝脏靶向性强、抗炎效果优、安全性高等优势。- 拉尼兰诺(泛PPAR激动剂)目前正在全球开展III期临床试验,用于治疗代谢功能障碍相关脂肪性肝炎(MASH)。2023年7月,拉尼兰诺被CDE纳入突破性治疗药物程序。拉尼兰诺是中国第一个进入临床III期的MASH药物,有望填补中国市场空白。呼吸系统创新药- 天晴速畅(吸入用布地奈德混悬液)是中国首款获批上市的布地奈德雾化剂型仿制药,打破了国内市场长期被原研垄断的局面,为国内气道慢性炎症患者带来了兼具有效性、安全性与经济性的高端制剂产品。该产品已被纳入集采范围,集团及时采取了一系列主动管理措施,包括管道下沉、拓展市场覆盖和集采外市场的二次开发,使其销售额在2024年实现了稳步增长。- 天韵(注射用多黏菌素E甲磺酸钠)于2021年首仿上市,是中国首款获批上市的注射用多黏菌素E甲磺酸钠,并于2023年成功纳入国家医保目录。目前,国内仅两家同通用名产品获批。集团通过积极的学术推广,不断拓展市场覆盖,天韵的销售额在2024年快速增长。外科/镇痛创新药- 泽普思(氟比洛芬凝胶贴膏)是中国首个获批上市的国产凝胶贴膏,连续多年蝉联外用镇痛市场份额第一位。氟比洛芬凝胶贴膏的销售额在过去几年保持增长态势,并在2024年实现了突破性增长。集团开发的第二代氟比洛芬贴剂预计将于2025年获批上市。其他- 2024年,第十批集采产品仅占本集团总收入的1%,集采风险基本出清。此外,集团自主研发的两款1类创新药,安柏尼(富马酸安奈克替尼胶囊)及安洛晴(枸橼酸依奉阿克胶囊),新增纳入医保目录,有望惠及更多患者。香港, 2025年3月21日- (亚太商讯 via SeaPRwire.com) -中国领先的创新研发驱动型医药集团-中国生物制药有限公司(「中国生物制药」或「公司」,连同附属公司统称「集团」)(股票编号:1177)公布截至2024年12月31日止12个月之经审核财务业绩。年内,集团录得收入约288.7亿元(人民币,下同),按年增长约10.2%。归属于母公司持有者应占盈利约35.0亿元,按年大幅增长约50.1%。基于归属于母公司持有者应占盈利计算之每股盈利约19.13分,按年显著增长约51.9%,该显著增长主要受惠于本年度收入明显增长及录得出售附属公司收益。扣除已终止经营业务之归属于母公司持有者应占盈利,应占联营公司及合营公司亏损(扣除相关税项及非控制权益),若干资产及负债之公允价值变动及一次性调整之减值,流动权益投资之公允价值亏损╱(利润)(扣除相关税项及非控制权益),股权激励费用(扣除相关税项及非控制权益),可转换债券债务部份之利息费用及汇兑(收益)╱亏损之影响后,经调整非《香港财务报告准则》归母净利润约人民币34.6亿元,按年增长约33.5%。集团流动资金保持充裕,资金储备总额约241.1亿元(计入流动资产之现金及银行结余约95.7亿元、计入非流动资产之银行存款约93.7亿元、理财管理产品总额约51.7亿元)。董事会建议派发末期股息每股4港仙(2023年:3港仙),连同已派发中期股息每股3港仙,全年合共派发股息每股7港仙(2023年:5港仙)。销售:强大销售体系持续发力,仿制药收入实现正增长集团以仿制为基石,全面推进创新转型,创新产品不断驱动销售增量,收入占比逐年提升。年内,创新产品收入达到120.6亿元,按年增长21.9%,占集团总收入比例达41.8%。年内,抗肿瘤用药之收入达约107.3亿元,占集团收入约37.2%。外科╱镇痛用药和肝病用药之收入分别约44.6亿元和34.4亿元,各占集团收入约15.4%和11.9%。此外,呼吸系统、心脑血管用药和其他等不同领域产品的销售持续贡献集团收入。其中,呼吸系统及心脑血管用药之收入分别占集团收入的约10.9%和7.5%。研发:全力以赴推动创新产品开发,积极申请各类专利集团继续专注抗肿瘤、肝病、呼吸系统和外科/镇痛四大治疗领域的新产品研发。截至报告期日,集团有在研创新药70个,其中抗肿瘤用药39个、肝病用药7个、呼吸系统用药13个、外科/镇痛用药6个,其他类用药5个。另外,集团还有65个在研仿制药産品。集团亦十分重视保护知识产权,鼓励成员企业积极申报各种专利,以提高核心竞争能力。年内,集团提交专利申请1,069项及获得专利发明授权349项。截至报告期日,集团累计有效专利及专利申请5,082项,累计获得专利发明授权1,958项。展望:聚焦核心业务和创新,继续推进「双路径」国际化发展战略中国医药市场凭借庞大的体量与递增的市场需求,在全球医药産业中占据关键地位。此外,医药産业作为关系国计民生的战略性産业,是国家政策引导和激励的重点扶持对象。同时,一系列的政策拓宽了创新药的定价空间,提升了药品可及性,创新药有望迎来更广阔的市场前景。集团秉承「专注创新、服务病患,成为全球领先的制药企业」的愿景,坚持全面创新,不断加大研发投入,自主研发能力持续增强,目前已构建完善的管线産品组合。同时,集团大力推进商务拓展和战略合作,力争成为全球制药与生物科技公司的最佳合作伙伴。目前,集团已进入创新成果收获期,预计到2027年,集团已上市创新産品数量将超过30个,创新産品收入占总收入比例将突破50%,这将强化集团在四大治疗领域的优势地位,为未来可持续发展注入强大动力。此外,集团以人工智能为核心驱动力,推动数字化战略升级,已完成DeepSeek、ChatGPT等AI模型的本地化部署,优化跨部门协作等关键业务,显著提升运营效率。同时,集团采用「双路径」国际化发展战略,加速创新发展。一方面,集团通过引进全球医药创新成果到中国,惠及中国病患;另一方面,集团拓展国际市场,瞄准全球尚未满足的临床需求。未来,集团将进一步聚焦核心业务和创新,持续提升四大治疗领域的研发效率和质量,并积极推进国际化布局,驱动业务高速增长和业绩稳步提升,为全球医药事业的发展贡献力量。有关中国生物制药有限公司(股票编号:1177)中国生物制药,连同其附属公司,是中国领先的创新研究和研发驱动型医药集团,业务覆盖医药研发平台、智慧化生産和强大销售体系全産业链。産品包括多种生物药和化学药,在肿瘤、肝病、呼吸系统、外科/镇痛四大治疗领域处于优势地位。公司于2000年在香港联交所上市,2013年入选MSCI全球标准指数之中国指数成分股;2018年入选恒生指数成分股;2020年入选恒生沪深港通生物科技50指数成分股、恒生中国(香港上市)25指数。中国生物制药连续五年荣登美国权威杂志《制药经理人》发布的「全球制药企业TOP50」,连续三年获评《福布斯》(亚洲) 「亚太最佳公司50强」。有关中国生物制药的进一步资料,请浏览: www.sinobiopharm.com Copyright 2025 亚太商讯 via SeaPRwire.com.

The Executive Centre Expands Its Premium Portfolio in Singapore With a New Centre at Ocean Financial Centre

- Launch of TEC’s 11th centre in Singapore, enhancing its footprint in the region.- Contemporary design featuring high-end amenities, including ergonomic furnishings and innovative workspaces.- Debut of Origo Café and Bar, showcasing an innovative array of refreshments to enhance the member experience.Singapore, Mar 21, 2025 - (ACN Newswire via SeaPRwire.com) - The Executive Centre (TEC), Asia’s leading premium flexible workspace provider, is delighted to announce the opening of its 11th centre in Singapore, located on level 22 of the prestigious Ocean Financial Centre. This expansive new centre encompasses over 21,000 square feet, and accommodates more than 300 workstations, further solidifying TEC’s presence within one of the Southeast Asia’s most sought-after business districts.Ocean Financial Centre is already home to three TEC centres, with occupancy levels close to 95%. This underscores the company’s unwavering commitment to delivering exceptional workspace solutions in this iconic building and to provide additional spaces to meet the growing demand. This latest centre opening is part of TEC's strategic expansion initiative, with more centres slated to open later this year in Singapore.The design of the new centre evokes contemporary elegance, featuring organic curves and warm wood elements in the main lounge area, creating an inviting ambiance for its members. In alignment with TEC's premium positioning, the centre is adorned with high-end finishes, height-adjustable standing desks, and ergonomic Herman Miller chairs, ensuring an unparalleled working environment.A notable highlight of the new centre is the debut of Origo Café and Bar, which presents an innovative array of refreshments, including a dedicated ice cream bar and craft beers on tap. This centre is The Executive Centre’s first in Singapore to hold a liquor license, enabling distinctive food and beverage pairings that transcend the traditional TEC Barista Bar experience. Additionally, Origo-branded coffee beans and merchandise will also be available for sale.In line with TEC's commitment to sustainability, the new centre incorporates Framery phone booth pods which provide exceptional soundproofing and optimal ventilation while minimising energy consumption. These environmentally conscious booths are fully recyclable at the end of their lifecycle, reflecting TEC’s dedication to sustainable innovation.Yvonne Lim, Managing Director of Southeast Asia at The Executive Centre, remarked, "We are profoundly excited to unveil our new centre at Ocean Financial Centre. This expansion not only epitomizes our commitment to providing exceptional workspace solutions but also enriches our community with innovative offerings such as Origo Café and Bar. We envision this centre as a vibrant nexus for professionals seeking a flexible and inspiring work environment."The Executive Centre’s new location at Ocean Financial Centre is poised to redefine the flexible workspace experience in Singapore, fostering collaboration and innovation among its esteemed members.About The Executive CentreThe Executive Centre (TEC) is Asia’s premium flexible workspace provider, opened its doors in Hong Kong in 1994 and today boasts over 220+ Centres in 36 cities and 16 markets. It is the third largest serviced office business in Asia.The Executive Centre caters to ambitious professionals and industry leaders looking for more than just an office space - they are looking for a place for their organisation to thrive. TEC has cultivated an environment designed for success with a global network spanning Greater China, Southeast Asia, North Asia, South Asia, the Middle East, and Australia, with sights to go further and grow faster. Each Executive Centre offers a prestigious address with the advanced infrastructure to pre-empt, meet, and exceed the needs of its Members. Walking with Members through every milestone and achievement, The Executive Centre empowers ambitious professionals and organisations to succeed.Privately owned and headquartered in Hong Kong, TEC provides first class Private and Shared Workspaces, Business Concierge Services, and Meeting & Events facilities to suit any business' needs.www.executivecentre.comPress EnquiriesThe Executive CentrePebble LeePebble_lee@executivecentre.com / +852 3951 9888 Copyright 2025 ACN Newswire via SeaPRwire.com.

巨星传奇将投资周杰伦2025「嘉年华」巡回演唱会三亚站

香港, 2025年3月20日 - (亚太商讯 via SeaPRwire.com) - 巨星传奇(06683)将投资周杰伦2025「嘉年华」巡回演唱会三亚站,继去年参与福州站、杭州站、长沙站、南京站及深圳站投资后,再度成为周杰伦《嘉年华》世界巡回演唱会的投资方之一。通过参与此类大型演唱会项目,公司旨在探索收入来源多元化的可能性,并致力于为股东及潜在投资者创造长期价值。展望未来,巨星传奇集团计划通过「IP+文旅」模式,将演唱会投资与 IP 运营结合,提升「周同学」IP 的国际影响力,并探索其旅游与经济潜力。公司拟通过创新策展,拓展 IP 多元化发展,例如开发更多联名商品、举办主题展览及推广线下互动活动,以进一步贴近粉丝与市场需求,增强「周同学」IP 的情感共鸣与文化价值。 Copyright 2025 亚太商讯 via SeaPRwire.com.

亨得利2024全年收入录得人民币10.44亿元

香港, 2025年3月20日 - (亚太商讯 via SeaPRwire.com) - 亨得利控股有限公司(「亨得利」或「公司」及其子公司「集团」,股票编号:3389)宣布截至2024年12月31日止12个月(「回顾年内」)之全年业绩。2024年,国际环境错综复杂,地缘政治冲突、区域性战乱及贸易保护主义愈演愈烈,世界经济增长动能依然偏弱。于中国而言,经济总量实现了新的突破,但风险隐患仍然较多。面对复杂的环境,本集团秉承「行稳致远」的原则,顺应市场调整业务,保生存、求发展,努力维护股东的利益。截至2024年12月31日止,本集团收入录得1,043,555,000元(人民币,下同;(2023年12月31日:1,421,454,000元),较去年同期下降了26.6%;高端消费配套业务等收入为688,104,000元(2023年12月31日:710,708,000元),较去年同期下降3.2%,大宗商品贸易收入为355,451,000元(2023年12月31日:710,746,000元),较去年同期下降50.0%。集团年度录得亏损约55,472,000元(2023年12月31日:溢利35,191,000元),股东应占亏损约为65,161,000元(2023年12月31日:溢利33,885,000元)。亏损的的主要原因是:销售及毛利下降,物业、厂房、设备的折旧费用上升及汇率波动导致营运单位产生外汇兑换亏损等。回顾年度内,中国经济压力承重,集团的高端消费配套业务受到了一定的影响。但集团采取多种措施应对复杂的经营环境,取得了较为明显的成效。年度内,高端消费配套业务的销售虽然有些许下降,但利润较去年同期仍有良好的提升。回顾年度内,集团的大宗商品国际贸易业务主要为铁矿石、动力煤及焦煤向中国内地的进口。受国际、国内经济环境的影响,铁矿需求走弱,矿砂及煤炭等产品的市场价格波动较大,致集团的国际大宗商品贸易额及利润较去年同期均有所下降。年度内,集团计划于墨西哥建设一个集清关、进口、运输、仓储于一体的大宗货物中转物流园区,致力于服务中国大型企业。2024年全球干散海运市场整体波动增长。集团紧抓市场上涨时机,大力拓展业务。年度内,集团成功开发了中国国家能源集团、澳洲兖矿、天元锰业集团、印度钢铁管理局有限公司、印度安塞乐米塔尔集团等一系列国内外知名大型矿山、电力和钢铁企业。在深耕传统运输航线外,首次开辟土耳其至中国铝矾土运输航线,幷签订了长期运输协议。本年度,集团海运业务收入与利润均取得了良好的成绩。当前,于全球来看,政治动荡不安趋势明显,经营环境依然复杂严峻。而中国内地经济运行除了外部环境变化带来的不利影响外,自身发展也面临一定的困难和挑战。但是,中国经济基础稳、韧性强、潜能大,长期向好的支撑条件和基本趋势没有变相信中国内地经济发展动能会持续增强,发展态势将持续向好。新的一年,本集团仍将坚持「行稳致远、持续经营」之原则,背靠中国内地「稳中求进、以进促稳」的经济发展环境,紧贴市场,谨慎而稳妥地继续国际贸易的进程,幷不断扩充与加强与国际贸易密切相关的国际海运业务,努力成长,以冀成为国际海运供应链中较强的一员,实现企业突破性的发展。集团亦仍将顺应市场需求,面向中国内地及国际双市场,不断提升商业空间一体化服务水平;调整高端名表配套产品的生产,同时展开有限多元化的业务进程,加强高端消费配套生产在珠宝、化妆品及手机等其他高端生活品领域的拓展,将商业空间美化服务扩充至生活空间美化服务领域等,继而成为高端消费配套生态链中不可或缺的一个独立环节。 Copyright 2025 亚太商讯 via SeaPRwire.com.

Brawijaya University Lecturer Develops IoT-based Chicken Coop Monitoring System

MALANG, E. JAVA, Indonesia, Mar 15, 2025 - (ACN Newswire via SeaPRwire.com) - A Lecturer at the Faculty of Animal Science at Brawijaya University, Danung Nur Adli Spt., MSc., MPt, has developed an integrated chicken coop monitoring system to increase the potential productivity of broiler chickens. The system uses the Internet of Things (IoT) and mobile apps.Malang, East Java - Danung Nur Adli (right), a Lecturer at the Faculty of Animal Science at Brawijaya University, explains the functions of his IoT-based chicken coop temperature monitoring system. (ANTARA FOTO/ARI BOWO SUCIPTO)The innovation was initiated in 2019, when Danung began designing ways to use technology in traditional 'open' model chicken coops to develop the economic value of male chicks that are often viewed as waste. "We didn't know what to do with the male chicks. They were usually raised to be sold as broiler chickens," Danung said in Malang, East Java, on Friday. "We have designed a real-time technology service for chickens, whose goal is to increase the productivity of broiler chickens."Danung's IoT-based chicken coop is also designed as an alternative to more sophisticated technologies, such as the TempTron, a temperature and humidity control device. Given the high cost to build a TempTron, which is specifically designed to maintain the stability of temperature and humidity in a closed chicken coop or 'close' house, Danung decided to design his innovation for farmers who use traditional open-type coops to raise chicken."So, we designed a microcontroller, then a sensor that works using a modem to transmit data about temperature and humidity," he said. "Chickens eat less when the air temperature is high. This requires a quick decision. If too late, it can affect their immunity, raising the potential to get sick, while the increase in cells per body weight also decreases," he explained.The mechanism allows each farmer to get real-time data on the temperature and humidity in their chicken coops within an estimated two to three minutes via their mobile phone.  Using the data, farmers can immediately take corrective action. For example, if the air temperature is hot, they can provide drinking water or nutritional intake to their chickens.In 2024, Danung's system received a funding grant for further development from Brawijaya University. His design also caught the attention of Communication and Digital Affairs Minister Meutya Hafid when she visited the East Java campus some time ago.Currently, Danung's chicken coop system is being used at several farms in Malang Regency, such as in Karangploso and Singosari. The innovation for livestock has received a positive response from chicken farmers as well, especially those from the millennial generation.For marketing the system, Danung is collaborating with Luthfan Bayu Zulkarnaen, a colleague and co-founder of Pemiara.id, a supplier of male chickens. "Bayu also helps to report on temperature developments, and provides input on what corrective actions to take," Danung said.For more information please click: https://ub.ac.idBrawijaya University: https://prasetya.ub.ac.id Editor: Primayanti, Copyright (c) ANTARA 2025  Copyright 2025 ACN Newswire via SeaPRwire.com.

TransNusa Successfully Launches Bali – Perth Route

JAKARTA, Mar 20, 2025 - (ACN Newswire via SeaPRwire.com) - As the international aviation industry players recovers, rebuilds, reassess and expands its route and service offerings, the newly transformed TransNusa has positioned itself to become the gateway to all things Indonesia.The airline, which has positioned itself strategically in its home country, can now connect international passengers to various precious and untouched vacation destinations in Indonesia from its bases in Bali and Jakarta.PT TransNusa Aviation Mandiri (TransNusa), Group Chief Executive Officer, Datuk Bernard Francis said, “TransNusa prides itself in enhancing passengers’ lifestyles by offering comfortable services and easier access to destinations that are world renowned for its unique and stunning landscape and natural offerings,” he said, adding that Indonesia has more than 17,000 islands that boosts its own stunning and vibrant panoramas.On details of the Perth-Bali route scheduled flights, Datuk Bernard explained, “Initially, TransNusa will operate three scheduled flights a week, which will be on Monday, Thursday and Saturday. From April 12, we will increase the frequency to four times a week by adding another flight on Tuesday and eventually increase the frequency to a daily flight from June 1 onwards.”TransNusa’s scheduled flight, 8B 080 (DPS-PER), will depart Bali at 09.10am from I Gusti Ngurah Rai International Airport and arrive the Perth Airport at 12.50pm. The flight, 8B 081 (PER-DPS), will depart Perth Airport at 13.35pm and arrive at I Gusti Ngurah Rai International Airport in Bali on 17.20pm. TransNusa will be utilising its Airbus A320 that has a seat capacity of 174 for this international route that has a 3 hours and 40 minutes flight duration.TransNusa started selling the flight tickets that are priced from as low as AUD 169, IDR 1.799.000, CNY 782, USD 163, and MYR 514 on January 15. The TransNusa flight tickets can be purchased at transnusa.co.id or any secure online travel agent.“With this Bali-Perth route launch, we want to be your local guide to all things Indonesia. We would like to become a gateway for our international passengers’ travel plans in Indonesia,” said, Datuk Francis, adding that TransNusa landed its maiden flight in Perth Airport at 12.50pm today.Datuk Francis explained further, “The Bali - Perth international route may be a golden route as the highest number of tourists, almost every year, in Bali are from Perth. However, for TransNusa, our responsibilities towards our passengers are not only to provide a comfortable flight between Perth and Bali but also to enhance lifestyles by connecting our West Australian passengers to other hidden gems in Indonesia.”“We have introduced this new international route in order to provide our passengers with additional travel choices and access to various other untouched paradise and secret getaway vacation destinations in Indonesia such as world-renowned diving haven, Manado.”“Apart from Bali and Manado, TransNusa also offers connecting flights to Raja Ampat in Sorong, which is home to the world’s richest coral reef and rare marine species, and to Indonesia’s Island of Spices, Ambon, among other local and international destinations,” said Datuk Bernard, adding that TransNusa can also connect passengers to Guangzhou, China from Bali.BREATHTAKING SCENARIES AT RAJA AMPAT, SORONGFor its international flights, TransNusa not only provide premium services with competitive ticket prices, but the airline also has attractive product bundles called SEAT, SEAT-PLUS and FLEXI-PRO."Our passengers will enjoy check-in baggage of between 15kgs to 30 kgs, depending on the product purchased,” Datuk Bernard said, explaining that the baggage offering was over and above the 7kgs limit offered as a passenger’s hand carry.“For the highest package, FLEXI-PRO, we provide more complete services such as free baggage 30kgs, free to choose seats, free food, and drinks, priority at check-in and boarding. In addition, TransNusa also provides its FLEXI-PRO passengers with the ability to be able to change their flight schedule without restrictions and obtain refund when needed.”TransNusa, which aims to ensure its passengers travel with ease and comfort, has also configured their A320s with a 174-seat configuration, which allows for passengers to enjoy about 30 inches of legroom, comparable to the experience passengers would get in a full-service airline."We are committed to providing affordable and competitive ticket prices, while still providing premium services to our customers.” Stressed Datuk Bernard.TransNusa, A Short HistoryTransNusa, which had to close it business operation in September 2020 due to impact of the Covid- 19 pandemic on the aviation industry, started operations again after injection of new shareholders and a new management team led by aviation expert, Datuk Bernard, in October 2022.Within 6 months, the airline introduced its first international route between Jakarta and Kuala Lumpur and celebrated its first-year anniversary for this route on April 14, 2024.“When we re-launched TransNusa in October 2022, we started from the bottom again. We had no aircraft or roadmap to follow. Everything was new because the pandemic had broken the aviation business operations boundaries. We re-created and customised our business operations and strategy model of being the first Premium Service Carrier based on the post-pandemic scenario,” Datuk Bernard explained.TransNusa launched its first international route between Jakarta and Kuala Lumpur in April, 2023, after which the airline successfully launched three more new international routes by the end of 2023. TransNusa’s aggressive international growth strategy combined with its domestic business operations approach has enabled the airline to be the fastest growing airline in South East Asia.Since the takeover of new shareholders and the injection of a new management team, TransNusa has been contributing and changing the aviation landscape in Indonesia. It has been making headlines in Malaysia, Singapore, China and around the world with news of being the first airline in Indonesia and the world to develop and introduce a new domestic route connecting Bali and Manado. TransNusa also became the second Indonesian airline to receive approval to fly to China and provided Indonesians with more pricing and route options to China.ENDSPrimary Media ContactTrina Thomas RajMobile and Watsapp: +6012 4992672E-mail: trina@myqaseh.orgAbout TransNusaEstablished in 2005, TransNusa started its operation by providing chartered flights. It began its commercial flights in 2011. After ceasing operations due to the Covid-19 pandemic, TransNusa relaunched itself in 2021 as a low-cost airline in its domestic market. In 2023, TransNusa introduced a new business model making it the first Premium Service Airline in the region. The new business model will apply only to its international routes. TransNusa introduced its first international route in April this year. The airline introduced its Jakarta – Kuala Lumpur round trip route and had its maiden flight on April 14. The airline is currently based in Jakarta Soekarno-Hatta International Airport.Passengers can book their flights on the TransNusa website (www.transnusa.co.id), through authorized travel agents in Singapore, Malaysia and Indonesia, or by contacting the airline's customer service centre at, +62216310888. For the Singaporean market, passengers can contact TransNusa’s General Sales Agent, Chariot Travels Pte Ltd, at +65 86602719 Copyright 2025 ACN Newswire via SeaPRwire.com.

云顶新耀启动嘉善工厂伊曲莫德生产建设项目 加速本地化供应布局

香港, 2025年3月19日 - (亚太商讯 via SeaPRwire.com) - 今日,云顶新耀宣布正式启动伊曲莫德(VELSIPITY®)位于嘉善工厂的生产建设项目,以支持该药物的本地化生产,进一步满足中国及亚洲市场对溃疡性结肠炎(UC)治疗的需求。该项目总投资达7000万元,预计投产后年产能可达5000万片,供应范围涵盖中国大陆、中国香港、中国澳门、中国台湾、韩国及新加坡等市场。随着溃疡性结肠炎(UC)患者数量的持续增长,中国市场对创新疗法的需求日益迫切。预计到2030年,中国溃疡性结肠炎患者将增至约100万,对更高效、安全、便捷的治疗方案提出了更高要求。伊曲莫德是一款每日一次口服的一线先进疗法,适用于中重度活动性UC患者,具有快速起效、临床缓解、黏膜愈合及良好安全性等优势。该药物已在多个国家和地区获批,并在2024年12月获中国国家药品监督管理局(NMPA)正式受理新药上市申请(NDA),此外已在中国香港获得NDA受理,并纳入粤港澳大湾区内地9市临床急需进口港澳药品医疗器械目录,正式惠及内地患者。嘉善工厂自2022年投入运营以来,已建立先进的生产设施和完善的质量保障体系,并符合全球良好生产规范(GMP)标准认证。在政府的大力支持下,该基地不仅承担伊曲莫德及其他创新药的生产任务,还将作为云顶新耀mRNA技术平台本地化的战略支点,支持mRNA肿瘤及自免治疗药物的从研发到商业化全流程,进一步强化公司在创新药物生产领域的核心竞争力。目前,云顶新耀已成功本地化经过临床验证的自主研发mRNA技术平台,并在个性化肿瘤治疗性疫苗(PCV)、肿瘤相关抗原疫苗(TAA)、免疫调节肿瘤疫苗和自体生成CAR-T四大方向实现全面布局。在近期投资者交流会上,公司披露了最新的mRNA管线进展,公司自主研发的首款mRNA个性化肿瘤治疗性疫苗EVM16已在北京大学肿瘤医院完成首例患者给药,EVM14及自体生成CAR-T项目亦取得重要的临床前研究数据,进一步验证了mRNA技术平台的潜力。云顶新耀的mRNA技术平台依托深度学习的自研"妙算"系统(EVER-NEO-1)新抗原预测算法,能够精准筛选高免疫原性肽段,优化mRNA疫苗抗原设计,提高免疫应答效果。经过四年多的持续优化,公司已成功迭代至第三代mRNA序列设计算法系统,其新抗原预测能力表现出行业领先水平,进一步夯实了云顶新耀在mRNA创新药物研发领域的技术壁垒。嘉善工厂生产建设项目的启动,不仅彰显了云顶新耀对伊曲莫德市场前景的信心,也为公司其他创新药的本地化供应奠定了基础。通过全面提升生产和质量管理体系,云顶新耀正在实现从研发、生产到商业化的全价值链条整合,进一步巩固其成为亚洲领先的全球综合性生物制药公司。 Copyright 2025 亚太商讯 via SeaPRwire.com.

MASH疾病领域的大市场、大需求

香港, 2025年3月19日 - (亚太商讯 via SeaPRwire.com) - 代谢相关脂肪性肝炎(MASH)已成为全球医药行业正在挖掘的潜力"富矿" - 2030年MASH市场规模将突破322亿美元,患者人数超4.8亿,至今FDA仅批准了一款药物。MASH作为一种与代谢紊乱相关的肝脏疾病,表现为肝脏中脂肪异常堆积,并伴随炎症和肝脏纤维化,可进展为肝硬化和肝细胞癌,是全球肝移植的主要病因,更显著增加了心血管疾病的风险。随着生活方式的改变,这个潜在的"健康杀手"早已随肥胖、糖尿病等代谢问题一起悄然而快速地蔓延。这使得近年来代谢性肝病市场规模持续迅猛增长。近日,中国创新药物医学大会暨2025CMAC年会在苏州召开,会议以"凝医学新知、聚创新之力"为主题,汇聚行业精英和权威学者,共同探讨创新药物医学的发展趋势与挑战。MASH作为近年来越来越受到大众、医学界和产业界关注的热点疾病,大会专为此设主题分论坛:"MASH 临床药物研发与创新技术:全球视野下的实践与应用"。作为国内代谢疾病创新药企代表,君圣泰医药创始人刘利平博士应邀出席,并做了《MASH临床研究与市场机遇》的专题报告,同与会各专家分享交流。MASH赛场迎来关键赛点,多靶点、联合机制成为趋势2024年3月,Madrigal公司的Resmetirom获批上市,成为FDA批准的首款MASH治疗药物,这一突破标志着MASH药物研发迎来关键破局点看、迈入新阶段。另一方面,MASH庞大的全球患者规模以及大众对于代谢和健康的综合改善诉求,使得Resmetirom远未能解决庞大的治疗需求与有限的治疗手段之间的巨大矛盾。市场需要更能有效改善肝脏组织学,且为患者带来综合获益的药物。目前,多款MASH在研药物已进入临床后期,然而单一机制药物往往难以兼顾MASH治疗的多重需求:既改善肝脏脂肪变性,又抑制肝脏炎症及纤维化,同时为MASH关联的代谢共病(如,糖尿病、肥胖、心血管疾病等)带来治疗获益。因此,具备多靶点、多功能作用的创新疗法正成为新的研发趋势。君圣泰医药正是这一趋势的领航者。其核心产品熊去氧胆小檗碱(HTD1801)是一款全球独创的双机制小分子药物,兼具激活AMPK与抑制NLRP3炎症小体生成。代谢调节与抗炎两种机制联合互补,有利于从根本上恢复代谢健康,在改善肝脏代谢、抑制炎症及纤维化等方面展现出独特的临床优势。这种双管齐下的治疗策略,为MASH患者提供了更全面的优选治疗方案,在临床中展现出差异化优势。HTD1801双机制"组合拳"出击,在国际赛场获认可HTD1801治疗MASH的有效性已在临床2a期研究被验证,在MASH合并2型糖尿病(T2DM)患者中,HTD1801能显著降低肝脏脂肪含量,并在改善肝损伤及血糖控制等方面表现优越。该临床2a期研究结果已发表在全球顶级期刊Nature Communications上,结果显示:- 经HTD1801治疗后,MASH合并T2DM患者的肝脏脂肪含量显著降低,降低幅度约为安慰剂组的3倍,同时多个肝损伤相关指标得到改善,提示HTD1801具有为肝脏带来组织学上显著获益的潜力。- 经HTD1801治疗后,可改善多个心血管代谢风险因素,对血糖、体重、LDL-C及甘油三酯等指标均有显著改善,为患者带来多维获益。HTD1801多次亮相于国际顶级肝病大会,在2024年举办的欧洲肝脏研究学会年会(EASL)和美国肝病研究协会肝病年会(AASLD)上,展示了多项该2a期临床试验的事后分析,数据显示:- HTD1801与"顶流药物"GLP-1受体激动剂联用,预计可为MASH合并T2DM的患者带来降糖、降脂以及减轻体重的进一步获益。- 改善致病根本:胰岛素抵抗是MASH发生的"种子",而在胰岛素抵抗更严重的患者中,HTD1801带来更大的治疗获益。- HTD1801具备高安全性,可成为慢性病(如MASH和T2DM)长期管理的理想选择。此外,与FDA获批药物Resmetirom相比,HTD1801在血糖控制和减重方面表现出更优的治疗效果。目前,HTD1801的IIb期临床试验正在顺利推进,已在2024年3月完成在中美两地的患者入组,预计将在2025年公布顶线数据。随着MASH成为代谢病领域的新焦点,全球创新药企正加速布局,以多靶点、多功能创新疗法为代表的新一代药物正在逐步推进临床。HTD1801凭借其兼具能量稳态调节与抗炎作用的独特机制和差异化临床优势,展现出广阔的治疗潜力。 Copyright 2025 亚太商讯 via SeaPRwire.com.

南山铝业国际香港招股 增长强劲的东南亚氧化铝龙头

香港, 2025年3月19日 - (亚太商讯 via SeaPRwire.com) - 近期,港股IPO市场持续升温,各行业龙头纷纷赴港上市,吸引全球投资者的关注和参与。3月17日,东南亚氧化铝龙头南山铝业国际(2610.HK)启动港股招股。本次IPO,南山铝业国际计划募资规模(绿鞋前)为23.5-27.8亿港元。发售价介乎26.6-31.5港元之间,每手100股,预计于3月25日登陆香港联交所主板。据了解,南山铝业国际(Nanshan Aluminium International) 是位于印度尼西亚廖内群岛省民丹岛经济特区的氧化铝生产商,市场份额稳居东南亚氧化铝行业首位。此外,南山铝业国际的母公司是中国电解铝行业龙头之一。目前南山铝业国际的采购、生产、销售环节均在印度尼西亚本土、东南亚或其他国家实现,是中资背景企业在海外实现外循环完整布局的典范。成本优势显著 稳健经营底盘稳固南山铝业国际主要面对全球市场提供优质冶金级氧化铝粉,凭借印度尼西亚得天独厚的资源优势,公司铝土矿、煤炭、员工成本均远低于行业水平,搭配其自建的160兆瓦发电厂、3.5万吨级深水码头、煤制气厂和专用水库等配套设施,进一步降低了公司的生产成本,使其成为全球氧化铝厂商中单吨成本最低的公司,单吨氧化铝生产成本仅约1700元人民币,仅为当前中国企业平均生产成本的55%。此外,公司于印度尼西亚的主要营运附属公司BAI所在的印度尼西亚廖内群岛省民丹岛经济特区让其享有长达20年的所得税豁免政策,为公司构筑了远超同业的成本护城河。值得一提的是,作为成品铝的上游产品,国际氧化铝价格受全球三大供给地区澳大利亚、几内亚和印度尼西亚的出口政策,开采和加工成本、远洋运费和同行业企业开工率等多种因素扰动,而南山铝业国际强大的成本优势,让其能更为从容应对市场波动,助力公司业务稳健经营。财务表现优异 行业高景气下成长前景可期在量价齐升的行业周期驱动下,南山铝业国际业绩呈现爆发式增长。财务数据显示,2021-2024年,公司营收分别为1.7亿、4.7亿、6.8亿、10.2亿美元,年复合增长率高达80%;同期公司净利润分别为0.4亿、1.0亿、1.7亿、4.6亿美元,年复合增长率高达126%。与此同时,南山铝业国际盈利能力持续提升。2021-2024年,公司毛利率分别为25.9%、24.0%、29.2%、50.6%。在24年氧化铝周期上升信道期间,公司依托印度尼西亚资源禀赋构筑的「成本凹地」稳定优势,成功将产品价格上行红利转化为盈利增长,推动自身毛利率增长至超过50%。此外,在2023年氧化铝下行周期内,公司毛利率依然保持接近30%的水平,展现出了公司的盈利韧性,印证了公司的成本优势。从行业前景看,2023年,印度尼西亚为东南亚氧化铝产能最大的国家(占该地区产能的70%以上)。受限于中国国内氧化铝、电解铝生产的产能规模限制,东南亚的氧化铝产量增速将显著高于全球水平,2019年至2023年复合年增长率达到23.3%,显著高于全球1.8%的年复合增长率,后续预计将以7.1%的速度增至2028年的851.5万吨,市场前景十分广阔,为南山铝业国际提供发展机遇。目前,南山铝业国际氧化铝年产能达200万吨,且其三期、四期扩建项目正在推进之中,预计于2026年底总产能将提升至400万吨。未来,随着其产能全面投产,公司东南亚第一市场地位将得到持续夯实。股东战略合作加持,赢得国际产业投资人广泛认可除控股股东南山铝业外,南山铝业国际还拥有齐力铝业、Santony家族等强有力的战略合作伙伴作为股东。公司第二大股东为齐力铝业,其为东南亚最大的综合铝业公司,并已于马来西亚上市,齐力铝业已经与公司签订了10年期氧化铝承购安排,与公司建立了稳定、长期的下游合作关系;公司第三大股东为Santony家族,公司与其保持了良好的关系,确保本公司优质铝土矿、煤炭等原料的稳定供应。本次上市过程中,公司也吸引了嘉能可Glencore、厦门象屿的间接附属公司香港拓威、瑞中国际、Indika Energy等多家知名大宗商品、能源贸易领域基石投资人的加持,并有望为公司带来更多的资源赋能和合作机会。 Copyright 2025 亚太商讯 via SeaPRwire.com.

康哲药业(00867)发布2024年度业绩:聚焦创新与专科突破 重塑增长动能

深圳, 2025年3月19日 - (亚太商讯 via SeaPRwire.com) - 3月17日,康哲药业发布2024年度业绩,公司全年实现营业收入人民币74.69亿元,同比下降6.8%;若全按药品销售收入计算,营业额为人民币86.22亿元,同比下降9.0%;实现净利润人民币16.13亿元,剔除相关资产减值损失计提后的正常化净利润为人民币17.14亿元。公告显示,公司业绩下滑主要受国采执行影响,三款未中标原研药2024年收入同比下降28.8%至人民币26.91亿元(全按药品销售收入计算)。然而,对于公司而言,2024年既是挑战中的"重塑之年",更是光芒初现的"突破之年"。公司整体业绩虽正经历短期阵痛,但独家药、创新药发展却不乏亮点,潜力已初步显现。公司2024年全按药品销售收入计算的独家产品及创新产品营收达人民币45.51亿元,同比增长4.1%,占总营业额的比重达到52.8%。本年度公司累计5款创新药进入商业化,但均处于早期市场导入阶段,未来随着已上市创新药逐步铺开大规模临床应用、快速放量,以及储备优质创新管线源源不断获批上市,公司将进入由独家药、创新药驱动的高质量、可持续发展新周期。公告显示,2024年康哲药业递交了重磅白癜风治疗创新药芦可替尼乳膏等2款新药的中国NDA,新增3项创新合作、3款医美产品合作。截至2024年底,公司已储备的短、中、长期创新管线总计近40项。此外,公司东南亚业务正蓄势待发,本年度已推动超过 5 款创新药递交上市注册申请,且联营公司的新加坡工厂前序准备工作基本完成,即将全面开展药品CDMO、销售推广业务,培育第二增长曲线。产品力为核心 夯实创新增长引擎作为深耕医药市场三十余年、已推动多款在售药品取得领先市场地位的药品商业化龙头,康哲药业在布局创新药时也秉持着敏锐的市场洞察,以一线需求指导立项,优选全球FIC、BIC创新药,其需符合"三好品种"筛选标准:具有学术差异化优势、较大市场潜力与良好竞争格局、及综合投资回报率高。从公司已上市的创新药来看,5款产品或是较市场既有品种有明显差异化优势,或在细分领域填补了市场空白,因而能为患者提供有价值的创新治疗方案。举例来说,用于慢性肾脏病(CKD)患者降磷的维福瑞(蔗糖羟基氧化铁咀嚼片)是经中国NMPA批准上市的首个铁基-非钙磷结合剂,并填补了国内12-18岁CKD4-5期或接受透析治疗的CKD患儿的降磷治疗用药空白,根据全球多项临床研究、真实世界研究资料(如发表在学术期刊International Urology and Nephrology、Clinical Nephrology的文献)及产品中国说明书,与其他磷结合剂相比,服用维福瑞的患者平均日服药片数减少了约50%,血磷达标率可提高95%;而益路取(替瑞奇珠单抗注射液)是一款靶向 IL-23p19亚基、治疗中重度斑块状银屑病的创新生物制剂,维持期只需每3个月给药一次,凭借其优异的长期疗效、便捷的用药周期和较好的安全性,有助于提升患者依从性。公司以优异的产品力为核心,并借助多年积累的丰富学术资源、推广经验,将有望实现已上市产品市场渗透力和品牌影响力的快速提升。公司目前处于NDA审评阶段、有望于2025年上市的2款创新药,芦可替尼乳膏、德昔度司他片,均被认为具备高市场潜力。根据公告,芦可替尼乳膏是截至目前美国FDA以及欧洲EMA批准的首个也是唯一一个局部 JAK 抑制剂白癜风复色产品,若成功上市,将为国内超千万深受困扰、无对症药物可用的白癜风患者带来治疗曙光。德昔度司他片用于治疗非透析成人CKD患者的贫血,并采用口服给药方式,中国III期临床试验结果显示,其在有效性、安全性和耐受性方面均表现良好。数据显示,我国CKD患者约有1.32亿,贫血是其常见并发症之一,产品上市后有望进一步满足CKD患者的贫血治疗需求。此外,公司已储备的、将于未来2至4年内获批上市的创新管线中,也有多款市场关注度高、业内评估有望成为FIC与BIC的大品种,如用于卒中治疗的注射用Y-3 、高选择性小分子口服JAK1抑制剂povorcitinib(非节段型白癜风、化脓性汗腺炎)、URAT1抑制剂ABP - 671(痛风)、抗IL-4Rα人源化单抗注射液 MG-K10(特应性皮炎)、口服改良型新药ZUNVEYL(阿尔茨海默病)等,可有力支撑公司未来业绩的持续增长。值得关注的是,康哲药业始终坚持"合作开发+自主研发"并举的高效创新路径,重视研发资源投入效益最大化。2018年至2024年,公司累计研发开支为人民币43.5亿元,占同期全按药品销售收入比重为7.6%,其中费用化研发投入为人民币8.8亿元,占同期全按药品销售收入的1.5%。公司通过较为审慎的研发投入,实现多个优质创新产品的成功立项、临床开发与上市,创新投入产出效率极高。此外,2024年底公司银行结余及现金达人民币37.07亿元,为持续加码创新、深耕前沿领域提供了充足保障。专科聚焦强化商业化体系 赋能产品价值释放强产品力与高效商业化能力协同发力,是康哲药业保持竞争优势的关键。康哲药业持续优化专科业务聚焦的商业化体系,形成以心脑血管/消化、皮肤/医美、眼科为核心的专科深耕格局,已积累丰富的专业推广网络和学术平台,为创新产品的成功商业化保驾护航。2021年起独立运营的皮肤医美业务公司"康哲美丽",正成长为中国领先、专业聚焦皮肤健康的创新型医药企业。康哲美丽已构建起以皮肤处方药为核心,并涵盖皮肤学级护肤品、轻医美产品的全产品矩阵。截至2024年底,其皮肤处方产品组合已全面覆盖白癜风、银屑病、AD、静脉炎、静脉曲张及化脓性汗腺炎等多种皮肤疾病;皮肤学级护肤品方面,专研敏感肌养护的"禾零舒缓产品系列"进一步完善,并新增"喜辽妥®壬二酸产品系列",为痘肌修护提供全套解决方案;轻医美业务方面,童颜针中国注册申请已获受理,并引入少女针、微晶瓷、脱细胞基质植入剂三款处于中国注册性临床阶段的再生类产品,进一步完善轻医美产品线。康哲美丽以多元的皮肤健康与美学产品矩阵,为不同皮肤健康需求人群提供全面、综合解决方案。同一时期开始独立运营的眼科业务公司"康哲维盛"则专注于眼科处方药、医疗器械及耗材的开发与商业化。在中国,眼病患者数量庞大,且人口增长和老龄化导致眼科疾病负担显著上升。康哲维盛借助眼科领域专业产品组合、广泛的网络及渠道资源等,持续巩固产品品牌力及学术地位,致力于成为中国领先的眼科药械公司。截至2024年底,康哲药业拥有约4,700名市场及推广人员,推广网络覆盖全国超5万家医院及医疗机构、约30万家零售药店。依托覆盖广泛的推广网络、执行高效的推广团队,公司围绕已上市创新药和核心独家产品,动态优化市场策略、推动真实世界研究及上市后临床研究,持续积累学术证据,强化产品学术影响力并加速转化为市场价值。同时,本年度内公司强化院外市场覆盖深度与广度,并通过线上线下融合、多渠道协同,实现院外引流与患者获益的双向提升。以东南亚为起点 培育海外业务第二增长曲线在深耕中国市场的同时,康哲药业加快国际化步伐,以东南亚为起点,借助当地对高性价比医药产品需求迅速增长这一有利契机,积极培育海外业务增长引擎,为公司长期、可持续增长注入新的动力。2024年,东南亚业务公司"康联达健康"结合区域特征与疾病谱特点,精准规划产品组合与商业化路径,多款产品的上市注册取得阶段性进展,为后续市场推广与销售落地奠定基础。本年度内,康联达健康获得创新产品povorcitinib(选择性小分子口服JAK1抑制剂,有望为相关自身免疫性和炎症性皮肤病患者带来新的治疗选择)东南亚十一国的独家许可权利。同时,康联达健康亦积极推进芦可替尼乳膏、益路取、莱芙兰、维图可、维福瑞等多款创新产品在东南亚及/或港澳台市场的上市注册工作。其中,芦可替尼乳膏已于澳门、香港获批上市,用于治疗白癜风;并已于新加坡、台湾市场递交注册申请。此外,康联达健康与君实生物合作的特瑞普利单抗(抗PD-1单抗)也于本年度内递交了马来西亚、菲律宾、印尼、泰国、越南市场的注册申请。CDMO业务方面,康哲药业联营公司PharmaGend位于新加坡大士的生产工厂已取得美国FDA的GMP认证,并顺利完成新加坡HSA现场审计,将为全球药企提供CDMO服务,同时也为康哲药业海外生产的供应链安全提供有力保障。站在新征程的起点,康哲药业以变应变、向新而行,坚定执行"创新驱动、效率优先、专科突破、全球布局"战略,重塑增长曲线,以更加多元、更有韧性的业务格局,迈向高质量发展的新阶段,将为患者提供更多优质治疗选择,为股东创造长期稳定回报。康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广,非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息,请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请,不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制,但康哲药业并无进行任何说明或保证、明述或暗示,或其他表述,对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述,该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证,存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测,康哲药业对该等第三方声明及预测不承担责任。 Copyright 2025 亚太商讯 via SeaPRwire.com.